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TAMOXIFEN METABOLITES CAN TARGET BOTH AROMATASE AND 
ESTROGEN RECEPTORS 
 
Breast cancer remains the most prevalent malignancy diagnosed in 
women. More than two thirds of all diagnosed breast cancers are estrogen 
receptor (ER)‐positive and are dependent on estrogen signaling. Drugs for the 
treatment of ER-positive breast cancer can be divided into three classes: 
selective estrogen receptor modulators (SERMs), selective estrogen receptor 
down-regulators (SERDs) and aromatase inhibitors (AIs). However, the efficacy 
and safety of SERMs, SERDs and AIs are compromised by side effects or tumor 
resistance. One possible way of improving treatment efficacy and safety profiles 
is to develop agents with dual aromatase inhibitory and ER modulatory activity.  
Over the past 30 years, tamoxifen, a SERM, has become the most widely 
used drug for the adjuvant treatment of breast cancer. The metabolism of 
tamoxifen has a complex profile involving both active and inactive metabolites, 
among which endoxifen, 4‐hydroxytamoxifen (4-HT) and norendoxifen (Nor) have 
been shown to have ER modulatory activity. Previous studies have also shown 
that norendoxifen is a potent AI in vitro. These preliminary studies support the 
utilization of tamoxifen metabolites as lead compounds for the development of 
dual AI/SERM(D) agents. 
xi 
Hydroxynorendoxifen (Hdn) was identified as a novel tamoxifen 
metabolite, with an average plasma concentration of 0.82 nM. Nor and Hdn were 
potent and relatively selective AIs, with Kis of 70 nM and 20 nM, respectively. Nor 
and Hdn have high binding affinity for ER-α and ER-β, with EC50 values less than 
35 nM. Nor and Hdn can inhibit breast cancer cell proliferation with high potency, 
with IG50s of 25 nM and 9 nM, respectively. Nor and Hdn can suppress 
progesterone receptor (PGR) mRNA expression level by reducing it by 68% and 
86%. Moreover, a series of Nor analogues were shown to have both potent 
aromatase inhibitory activity and high ERs binding affinity. 
Results from this dissertation will contribute to three aspects: 1) the 
identification of Hdn as a tamoxifen metabolite illustrated a more comprehensive 
metabolism profile of tamoxifen; 2) the data suggest Nor and Hdn possess dual 
aromatase inhibitory and ER antagonistic activity; 3) a series of Nor analogues 
were characterized as lead compounds for the development of dual AI/SERM(D) 
agents. 
 
David A. Flockhart, M.D., Ph.D., Chair 
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CHAPTER 1: INTRODUCTION 
1.1 Breast cancer and its classification 
Breast cancer is the most prevalent cancer diagnosed in women and the 
second most common cancer worldwide after lung cancer. Breast cancer 
remains a major threat to the lives of women, even though the mortality caused 
by breast cancer has declined in the past two decades. 
Breast cancer is a heterogeneous disease characterized by its variable 
morphological features, different molecular subtypes and diverse clinical 
outcomes. According to different scientific criteria and/or clinical practices, three 
classification schemes of breast cancer were established: 1) 
immunohistochemical (IHC) classification based on biomarkers; 2) molecular 
classification based on gene expression profiling; 3) histopathological 
classification based on morphological features1. 
The first classification scheme, IHC classification, was established based 
on well-defined biomarkers, which played important roles for the development 
and invasion of breast cancer. Using this classification scheme, breast cancers 
are grouped into subtypes based on the hormone receptors (HRs) status and the 
expression status of human epidermal growth factor receptor 2 (HER2). Breast 
cancers that contain either estrogen receptors (ERs) or progesterone receptors 
(PRs) are HR-positive, which depends on estrogen signaling or progesterone 
signaling or both. Otherwise, they are HR-negative breast cancer. Breast cancers 
that overexpress HER2 or have extra copies of the HER2 gene are called HER2-
2 
positive. Otherwise, they are HER2-negative breast cancer. Breast cancers that 
don’t have HRs or overexpress HER2 are classified as triple-negative. 
Currently, IHC classification along with clinical pathologic variables, such 
as nodal involvement, tumor size, histologic type, tumor grade, and surgical 
margins, are commonly used to select treatment and to predict disease 
prognosis2. Therefore, IHC classification has been widely applied by diagnostic 
laboratories to classify breast cancer types and to help choose the optimal 
treatment approach3. 
The second classification scheme, molecular classification, was 
established based on gene expression profiling using hierarchical clustering of 
groups of genes based on the similarity of gene expression patterns. Using this 
classification scheme, breast cancers are classified in five subtypes: luminal A, 
luminal B, HER2-postive, basal-like and claudin-low. 
Although this classification scheme of breast cancers has not been 
implemented clinically for patient management, it links the molecular biology of 
breast cancers and breast cancer cells’ behavior in the five subtypes. In this 
context, molecular classification has prognostic value and may be predictive of 
response to chemotherapy.  
The third classification scheme, histopathological classification, was 
established based on the morphological features of the tumors. Using this 
classification scheme, breast cancers can be divided into in situ carcinoma and 
invasive (infiltrating) carcinoma. Breast carcinoma in situ (BCIS) is further sub-
classified as either lobular carcinoma in situ (LCIS) or ductal carcinoma in situ 
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(DCIS). LCIS is considerably less common than its DCIS counterpart and 
encompasses a heterogeneous group of tumors. DCIS has traditionally been 
further subclassified based on the architectural features of the tumor which has 
given rise to 5 subtypes: Comedo, Cribiform, Micropapillary, Papillary and Solid4. 
A major drawback of this classification scheme is that about 70%-80% of 
the all breast cancers will belong to either one of the two major categories, 
namely invasive ductal carcinomas, not otherwise specified (IDCs NOS), or 
invasive lobular carcinoma (ILC). Hence, this classification scheme has minimal 
prognostic and predictive implications and its clinical utilization is quite modest5.  
 
1.2 Breast cancer management and treatment 
Currently, clinical breast examination, mammography and ultrasound are 
the standards for the diagnosis of breast cancer. While, multidisciplinary 
management including clinical, radiological, pathological and core biopsy has 
been applied for the diagnosis of breast cancer6. Magnetic resonance imaging 
(MRI) has been shown to be useful in many cases to determine malignancy 
extent6. 
Usually, wide local excision breast conserving surgery is preferred. 
Mastectomy is mainly recommended when wide local excision breast conserving 
surgery is not suitable due to tumor size or multifocal disease, or for the patients 
requesting mastectomy. All the patients who received breast conserving surgery 
are also treated with breast radiotherapy. Chemotherapy or endocrine therapy 
4 
may be given before breast conserving surgery to reduce tumor size and 
facilitate breast conservation.  
After breast surgery, an adjuvant therapy plan is commonly decided by the 
pathology report including histological grade, HRs expression (ERs and PRs) 
status and HER2 expression status. Endocrine therapy for the treatment of ER-
positive breast cancer can be divided into three classes: selective estrogen 
receptor modulators (SERMs), selective estrogen receptor down-regulators 
(SERDs) and aromatase inhibitors (AIs). Both pre-menopausal and post-
menopausal women can be treated with SERMs for the ER-positive breast 
cancer. The US Food and Drug Administration (FDA) has approved three 
SERMs (tamoxifen, raloxifene and toremifene) for the prevention or treatment of 
ER-positive breast cancer, among them, tamoxifen has become the most widely 
used SERM. Only one SERD (fulvestrant) was approved by US FDA for the 
treatment of ER-positive metastatic breast cancer in post-menopausal women. 
Currently, the US FDA approved aromatase inhibitors (AIs), including letrozole, 
anastrozole and exemestene, are superior to tamoxifen for the treatment of ER-
positive breast cancer in post-menopausal women.  
Besides the available endocrine therapy, for patients with HER2-positive 
breast cancer, HER2-targeted medications, including trastuzumab, pertuzumab, 
lapatinib and trastuzumab emtansine (T-DM1), have been shown to have survival 
benefits, even though these drugs have different mechanisms. Among them, 
trastuzumab and pertuzumab are monoclonal antibodies that target the HER2 
extracellular domain and block its activation. Lapatinib is a small-molecule kinase 
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inhibitor targeting HER2 and epidermal growth factor receptor (EGFR). T-DM1 is 
an antibody-drug conjugate (ADC), in which the monoclonal antibody 
trastuzumab is linked to a small-molecule microtubule inhibitor mertansine 
(DM1). Since patients with triple-negative breast cancer (TNBC) lack expression 
of HRs and do not exhibit amplification of HER2, they will not benefit from 
SERMs, AIs or HER2-targeted drugs. Until now, there is no approved targeted 
therapy for the treatment of TNBC. Chemotherapy, combined with surgery and 
radiation therapy, is the only treatment option for TNBC. 
 
1.3 Estrogen receptor-positive cancer and estrogen signaling 
More than two thirds of all diagnosed breast cancers are estrogen 
receptor (ER)‐positive and are dependent on estrogen signaling. ER has two 
isoforms, ER-α and ER-β, belonging to a superfamily of nuclear hormone 
receptors that function as transcriptional factors when bound by ligands. 
Estrogenic actions in both normal breast cells and breast cancer cells are 
mediated primarily by ER-α. Since ER-α is involved in the pathogenesis of breast 
cancer, it has been considered as a target for the treatment of breast cancer for a 
long time7.  
ER-α is encoded by a gene localized on chromosome 6q24-27, and ER-β 
is encoded by a gene located on chromosome 14q21-22. ER-α has 595 amino 
acids, while ER-β has 530 amino acids. Both ER-α and ER-β have similar 
structures and their functional domains can be divided into five regions: A/B, C, 
D, E and F domains. Among these five domains, C domain is a DNA-binding 
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domain (DBD) for DNA recognition and binding, whereas E domain is a 
hormone-binding domain (HBD) or ligand-biding domain for ligand binding. The 
DBDs of ER-α and ER-β are highly conserved with a 95% homology, while, their 
HBDs are less conserved with only 53% homology. In addition, there are two 
distinct transactivation domains located in A/B and E regions, termed activation 
factor-1 (AF-1) and activation factor-2 (AF-2), respectively. Transcriptional 
activation mediated by ERs is stimulated through AF-1 and AF-2 (hormone-
dependent), among them, AF-1 is hormone-independent, while AF-2 is hormone-
dependent8.  
Estrogens play important roles in sex determination, fertility, pregnancy, 
immune response, bone formation and cardiovascular system. Estrogens share a 
common four-ring chemical structure with cholesterol, because they are 
derivatives of cholesterol, which can be converted into progesterones, then into 
androgens and finally into estrogens by a series of enzymatic reactions9. There 
are three primary types of estrogens: estrone (E1), estradiol (17β-estradiol, E2) 
and estriol (E3). These estrogens are named based on how many hydroxyl 
groups they have. E2 has the highest binding affinity for ERs, followed by E1 and 
then E310. E2 is converted from testosterone and it is the major estrogen in pre-
menopausal women. E1 is converted from androstenedione and it is the major 
estrogen in post-menopausal women. During pregnancy, E3 is converted from 
16-α-hydroxyandrostenedione and it is the major estrogen in pregnant women.  
ER-α is usually in its inactive state by forming a complex with proteins 
including heat shock protein 70, heat shock protein 90, cyclophilin 40, FKBP51 
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and FKBP52. Estrogens diffuse through cellular plasma and then nuclear 
members and finally bind to ER-α through its HBD11. This binding leads to the 
dissociation of inactive complex and then activates the conformational changes 
for dimerization. Binding of estrogens to ER-α can trigger recruitment of various 
cellular factors in a complex that alters chromatin structure and facilitates binding 
of RNA polymerase II transcriptional activation11. Therefore, estrogen-ER 
complex functions as a transcriptional activator, which is able to induce promoter 
gene expression. 
The dimeric ER-αs bind to DNA with high affinity through their DBD at 
specific sites called estrogen-responsive elements (EREs) in the promoter region 
of estrogen-responsive genes. Then, coactivators like members of the p160 
steroid receptor coactivator (SRC) family (SRC-1, Tif-2/GRIP1 and SRC-3/AIB1) 
can interact with ER-α via common α-helical peptide sequences. The α-helical 
peptide sequences are hydrophobic and amphiphatic motif LXXLL (L = leucine 
and X = any amino acid). The SRC family interact with the histone 
acetyltransferases, cyclic adenosine monophosphate (cAMP) response element-
binding protein (CREB)-binding protein (CBP), and p300, which acetylate, and 
with coactivator-associated arginine methyltransferase 1 (CARM1) and protein 
arginine N-methyltransferase 1 (PRMT1), which methylate histones within the 
nucleosomes11. An RNA helicase A (RHA), and an ATP-dependent chromatin 
remodeling complex, SWItch/Sucrose NonFermentable (SW1/SNF), are 
recruited. The resultant coactivator complex modifies the nucleosomes and alters 
the surrounding chromatin to allow access to the activating transcription factor 
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proteins, TATA-binding protein, and RNA polymerase II machinery, and 
transcription ensues12. 
Well-known estrogen-responsive genes include progesterone receptor 
(PR), trefoil factor 1/presenelin-2 (TFF1/pS2), B-cell CLL/lymphoma (BCL2), 
cathepsin D, cyclin D1, c-Myc and cyclin D1 (CCND1) genes. 
 
1.4 Selective estrogen receptor modulators (SERMs) 
Selective estrogen receptor modulators (SERMs) are a diverse group of 
compounds that function as agonists or antagonists for ERs with a target tissue-
specific profile. SERMs are used for various indications, including treatment of 
breast cancer, osteoporosis, and menopausal symptoms. When SERMs act as 
agonists, their mechanisms of action include binding to ERs, then triggering the 
dimerization of ERs, binding to DNA and finally activating transcription after 
recruiting a series of coactivators. When SERMs act as antagonists, their 
mechanisms of action include binding to ERs and favoring a corepressor binding 
conformation instead of coactivator binding, thus blocking the activation of 
estrogen-responsive genes13. 
The tissue-specific profile of SERMs may be caused by several of factors: 
1) SERMs have different binding affinities for ER subtypes; 2) ER subtypes are 
differently expressed in target tissues; 3) co-factors are differently expressed in 
target tissues; 4) the binding of SERMs may induce different ERs conformational 
changes that further influence the dimerization and binding to co-factors. 
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Currently, US FDA approved SERMs can be divided into two categories 
based on their chemical structures: 1) triphenylethylene derivatives (tamoxifen, 
toremifene, ospemifene and clomiphene); 2) benzothiophene derivatives 
(raloxifene and bazedoxifene). 
 
1.4.1 Triphenylethylene derivatives 
Tamoxifen (developed by AstraZeneca) is a first generation SERM 
developed in 1970s and was approved by US FDA in 1977. It is the first-line 
endocrine therapy as adjuvant therapy for both early and metastatic (advanced) 
ER-positive breast cancer, and it has also been approved by US FDA for the 
prevention of breast cancer development in high-risk women. Tamoxifen acts as 
an ER antagonist in breast cancer cells, while, tamoxifen displays ER agonistic 
effects in uterus, bone, and vascular venous system. The different actions of 
tamoxifen in various tissues may be caused by the various expressions of the co-
factor proteins. For example, SRC1, a co-factor promoted by tamoxifen, is highly 
expressed in uterine cells. However, it is lowly expressed in breast cancer cells. 
Treatment of tamoxifen increase the risks of several side effects including 
endometrial cancer, hot flashes, thromboembolic events, ocular toxicity, stroke 
and pulmonary embolism14. The occurrence of these side effects can be 
attributed to the partial estrogen agonistic effects of tamoxifen, for example, the 
increased risks of endometrial cancer and thromboembolic events in the uterus 
and vascular venous system. Several studies have shown that the use of 
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tamoxifen is associated with increased level of systemic estrogen, however, the 
mechanism is still unknown15,16. 
Toremifene (developed by GTx Inc.) is a tamoxifen analogue by the 
presence of a chlorine atom at the 4 position, and its preclinical and clinical 
activities are very similar to those of tamoxifen. It has been approved by US FDA 
as a treatment of advanced (metastatic) ER-positive breast cancer in post-
menopausal women. Because the similarities between toremifene and tamoxifen, 
the functional mechanisms and safety profiles of toremifene is similar to 
tamoxifen17. 
Ospemifene (developed by Shionogi Inc.) is a tamoxifen analogue with a 
chlorine atom at the 4 position but without the 2-(dime-thylamino) ethoxy region. 
It has been approved by US FDA in 2013 for the treatment of dyspareunia 
(usually moderate to severe). Dyspareunia is associated with vulvar and vaginal 
atrophy because of menopause. Similar to tamoxifen and toremifene, 
ospemifene has anti-estrogenic effect in breast tissue, estrogenic effect in bone 
and partial ER agonist effects in uterine and vaginal tissues. Ospemifene is the 
only SERM with nearly full estrogen agonistic effect on the vaginal epithelium, 
and it has relatively weaker estrogen agonistic effects on endometrium. This 
unique feature of ospemifene makes it the only SERMs for the treatment of 
dyspareunia. The treatment of ospemifene is associated with side effects 
including hot flashes, vaginal discharge, muscle spasms18. 
Clomiphene (developed by Sanofi-aventis U.S. LLC, now Sanofi) has a 
different indication from the other SERMs. It has a similar chemical structure to 
11 
tamoxifen and was approved by US FDA in 1967 for the treatment of ovulatory 
dysfunction. Clomiphene remains a first-line drug for the treatment of anovulatory 
infertility 19.  
 
1.4.2 Benzothiophene derivatives 
Raloxifene (developed by Eli Lilly& Co) is a second generation SERM with 
a polyhydroxy phenol benzothiophene that has different tissue-specific effects 
compared to tamoxifen. It has been approved by US FDA for the treatment and 
prevention of post-menopausal women’s osteoporosis and for the reduction in 
risk of invasive breast cancer in post-menopausal women with osteoporosis 20. 
Bazedoxifene (developed by Wyeth Pharmaceuticals, Inc., a wholly owned 
subsidiary of Pfizer, Inc.) is a third generation SERM with a core binding domain 
consisting of a 2-phenyl-3-methyl indole and a hexamethylenediamine ring at the 
side chain terminus. It has been approved for the treatment of vasomotor 
symptoms due to menopause and for the prevention of post-menopausal 
women’s osteoporosis 21. 
 
1.5 Selective estrogen receptor down-regulators (SERDs) 
Selective estrogen receptor down-regulators (SERDs) are distinguishable 
from SERMs pharmacologically. SERDs function as pure ER antagonists, which 
can lead to impaired dimerization, increased ER turnover and disrupted nuclear 
localization22. 
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1.5.1 Fulvestrant 
Fulvestrant (developed by AstraZeneca) is the only SERD approved by 
US FDA, and its indication is for the treatment of ER-positive metastatic breast 
cancer in post-menopausal women. Binding of fulvestrant to ERs will lead to ER 
degradation and loss of the ER protein. Both in vitro and in vivo studies have 
shown that after binding of fulvestrant, the ER turnover is increased and nuclear 
localization is disrupted with a reduced number of detectable ER molecules23. 
 
1.6 Aromatase and aromatase inhibitors 
1.6.1 Aromatase 
Aromatase (CYP19) is encoded by CYP19A1 gene residing on 
chromosome 15q21 in humans and it is the sole member. Aromatase is the only 
enzyme responsible for the production of E2 from testosterone, E1 from 
androstenedione and E3 from 16-α-hydroxyandrostenedione by demethylation 
and subsequent aromatization. Specifically, aromatase catalyzes the conversion 
of C19-androgens to C18-estrogens through a 3-step reaction that sequentially 
generates 19-hydroxy and 19-aldehyde intermediates before aromatase24. 
Aromatase belongs to the cytochrome P450 (CYP) superfamily, which 
plays dominant roles in drug metabolism. This superfamily includes various CYP 
isoforms, such as CYP1A2, CYP2A6, CYP3A4, CYP3A5, CYP2C19 and 
CYP2D6. In human liver, CYP1A2 accounts for 13% of the CYP content and 
catalyzes the primary metabolic route for a number of important drugs, including 
caffeine, clozapine, flutamide, lidocaine, olanzapine and zolmitriptan25. CYP2A6 
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is a major CYP in human liver, specifically involved in the oxidative metabolism of 
nicotine. It is also involved in the metabolism of pharmaceutical agents such as 
methoxyflurane, halothane, losigamone, letrozole, valproic acid, disulfiram and 
fadrozole26,27. CYP3A4 and CYP3A5 account for about 50% of the CYP content 
and are the predominant CYP contributors to metabolism in human liver, 
accounting for 40-60% of the oxidative metabolism of marketed drugs28. 
CYP2C19 can metabolize 10-15% of drugs on the market, including omeprazole, 
mephenytoin, proguanil and diazepam29. CYP2D6 can metabolize about 25% of 
drugs in current clinical use, including tamoxifen30. Any proposed new drug that 
undergoes significant metabolism by CYP superfamily should be evaluated for 
CYPs inhibition and further for drug-drug interactions (DDIs).  
However, unlike most of the CYPs, aromatase is not highly expressed in 
healthy human livers and hepatic aromatase activity is minimal. In humans, 
aromatase is expressed in ovaries as well as numerous extragonadal tissues 
including testes, placenta, mesenchymal cells of adipose tissue (but not the lipid‐
filled mature adipocytes), osteoblasts, chondrocytes of bone, vascular smooth 
muscle, endothelium and brain31. In pre‐menopausal women, aromatase is 
mainly present in ovaries, while, in the post‐menopausal women, adipose is the 
largest tissue containing aromatase. Therefore, aromatase activity is high in the 
ovaries of pre-menopausal women, while, aromatase activity is high in the 
adipose tissue of post-menopausal women. In addition, aromatase expression 
and thus aromatase activity have been shown to be greatly increased in 
malignant but not normal breast tissue. 
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The crystal structure of human aromatase has demonstrated that it is a 
heterodimer made up of a CYP aromatase and a ubiquitous NADPH CYP 
reductase. The catalytic domain of aromatase contains a heme group in a steroid 
binding site32.  
 
1.6.2 Aromatase inhibitors 
The conversion from peripheral androgens to estrogens by aromatase is 
the primary source of estrogen production in post-menopausal women and in 
women, who have reduced or eliminated ovarian function after a pathological 
change or medical intervention. Therefore, aromatase has become an important 
target for the treatment of ER-positive breast cancer in post-menopausal women. 
Aromatase inhibitors (AIs) were developed to reduce the peripheral estrogen 
production in post-menopausal women by blocking aromatase activity and in turn 
inhibit the tumor growth. 
Currently, the US FDA has approved three third generation AIs: letrozole, 
anastrozole and exemestane. These three AIs can be classified as steroidal 
(exemestane) and non-steroidal (letrozole and anastrozole) compounds. 
Steroidal AIs are analogues of natural aromatase substrates, testosterone and 
androstenedione. They can bind competitively to the binding site of aromatase, 
forming tight, irreversible covalent bonds that result in permanent enzyme 
inactivation. Reactivation of aromatase activity is dependent on further synthesis 
of aromatase. Non-steroidal AIs interact with the heme moiety inside the binding 
site of aromatase and in turn inhibit steroidal aromatization. Thus, sustained 
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aromatase inhibition depends on the continuous presence of drug. In vivo tracer 
studies indicate that third generation AIs may inhibit total systemic estrogen level 
by 98%, there are several studies indicating systemic estrogen level to be 
sustained at 20-40% of pre-treatment levels on therapy33. In post-menopausal 
women with advanced disease, both steroidal and non-steroidal AIs have shown 
good clinical efficacy without cross-resistance between the two groups, and 
similarly acceptable short-term toxicity profiles 34. 
Letrozole (developed by Novartis Pharmaceuticals Corp.) is a non-
steroidal AI approved by US FDA for the adjuvant treatment of early ER-positive 
breast cancer in post-menopausal women or extended adjuvant treatment of 
early breast cancer in post-menopausal women after five years of adjuvant 
tamoxifen treatment. Letrozole has also been approved for the adjuvant 
treatment of metastatic breast cancer in post-menopausal women35. 
Anastrozole (developed by AstraZeneca) is also a non-steroidal AI 
approved by the US FDA for the adjuvant treatment of early ER-positive breast 
cancer in post-menopausal women. It has also been approved as first-line 
treatment of ER-positive or unknown locally advanced (metastatic) breast cancer 
and second-line adjuvant treatment of metastatic breast cancer with disease 
progression after tamoxifen therapy36. 
Exemestane (developed by Pfizer Inc.) is a steroidal AI approved by the 
US FDA for the adjuvant treatment of early ER-positive breast cancer in post-
menopausal women who have received two to three years of tamoxifen. It has 
also been approved for the treatment of advanced breast cancer in post-
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menopausal women whose disease has progressed following tamoxifen 
therapy37. 
 
1.7 Tamoxifen and its metabolites 
Over the past 30 years, tamoxifen, a SERM, has been the most widely 
used drug for the adjuvant treatment and prevention of both early and advanced 
(metastatic) ER-positive breast cancer. Tamoxifen itself has low binding affinity to 
ER and thus is considered to be a pro-drug functioning through its active 
metabolites. The metabolism of tamoxifen has a complex profile involving both 
active and inactive metabolites by both phase I and phase II liver enzymes. The 
metabolites of tamoxifen can be classified as primary and secondary metabolites 
based on their sequence and amount. According to an in vitro extensive study by 
Dr. Desta, the primary metabolites of tamoxifen include N-desmethyl-tamoxifen 
(N-DMT), 4-hydroxy-tamoxifen (4-HT), α-hydroxy-tamoxifen (α-HT), 3-hydroxy-
tamoxifen (3-HT) and 4’-hydroxy-tamoxifen (4’-HT). The secondary metabolites 
of tamoxifen include 4-hydroxy-N-desmethyl-tamoxifen (endoxifen), N-
didesmethyl-tamoxifen (N,N-DDMT), 3,4-dihydroxy-tamoxifen (3,4-DHT) and α-
hydroxy-N-desmethyl-tamoxifen (α-HN-DMT) 38. The primary major metabolite of 
tamoxifen, N-DMT, is an inactive compound with a weak anti-estrogen effect and 
is mainly formed via CYP3A4/5 (minor formation via CYP2C9, CYP2C19 and 
CYP2B6). The minor primary metabolite of tamoxifen, 4-HT, is the first 
characterized active metabolite possessing high binding affinity for ERs and 
potent activity in suppressing estrogen-responsive cell growth and estrogen-
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responsive genes 39. The formation of 4-HT is mainly via CYP2D6 and other 
CYPs including CYP2C9, CYP2C19 and CYP3A play less important roles. Other 
minor primary metabolites of tamoxifen, including α-HT, 3-HT and 4’-HT, are 
mainly formed by CYP3A4/5, CYP3A4/5 and CYP2B6. 
Besides these primary metabolites, a secondary tamoxifen metabolite, 
endoxifen, has been shown to have potent activity similar to 4-HT with respect to 
ERs binding affinity, inhibition of estrogen-responsive cell growth and estrogen-
responsive gene expression 40. Since clinical data has shown that the plasma 
concentration of endoxifen is 5- to 7-fold higher than that of 4-HT in patients, 
endoxifen is considered the most important active metabolite of tamoxifen41. 
Endoxifen is formed from N-DMT and 4-HT mainly via CYP2D6 and CYP3A4/5, 
respectively. 
Figure 1 shows the chemical structures of tamoxifen and its important 
metabolites, including tamoxifen, N-DMT, 4-HT, endoxifen, N,N-DDMT and Z-
norendoxifen. Table 1 shows the plasma concentrations of tamoxifen, N-DMT, 4-
HT and norendoxifen reported by Dr. Flockhart’s and Dr. Schwab’s groups42-44.  
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Figure 1. Chemical structures of tamoxifen and its representative 
metabolites 
 
Table 1. Plasma concentrations of tamoxifen, N-DMT, 4-HT and 
norendoxifen 
 Average plasma concentration (nM)
Tamoxifen 372.5 
N-DMT 653.4 
4-HT 9.5 
Endoxifen 78.0 
Norendoxifen 3 
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In 20014, Dr. Lien’s group reported a study for target tissue concentration 
of tamoxifen and its metabolites. This study includes 108 serum samples, 62 
breast cancer tissue sample and 52 normal breast tissue samples for analysis of 
tamoxifen and its metabolite concentrations. The median (mean) concentration of 
tamoxifen in subjects taking 20 mg/day dosage is 83.6 (77.1) ng/ml. The median 
concentrations of tamoxifen and N-DMT in the normal breast tissues and breast 
cancer tissues were 5-11 times higher than those observed in serum. Unlike 4-
HT, tamoxifen, N-DMT and N,N-DDMT in serum were related to their levels in 
normal breast tissue and breast cancer tissues. For 4-HT, in normal breast tissue 
there were lower correlations between 4HT and tamoxifen, N-DMT, and N,N-
DDMT. While in tumor tissue there were high correlations45. 
Other enzymatic conversions from primary metabolites to secondary 
metabolites include: N-DMT can be metabolized to N,N-DDMT and α-NH-
desmethyl-tamoxifen predominantly via CYP3A4/5; 4-HT, which can be 
metabolized to 3,4-DHT via CYP3A4/538. 
Besides the ER antagonistic activity of endoxifen, it has also been shown 
to inhibit recombinant human aromatase with an IC50 value of 4000 nM via a non-
competitive mechanism in vitro. Previous studies by our group identified another 
metabolite of tamoxifen, N,N-didesmethyl-4-hydroxy-tamoxifen, which was the 
demethylated product of endoxifen and thus was named norendoxifen (Nor) 46. 
Norendoxifen has been shown to inhibit recombinant human aromatase with a Ki 
value of 70 ± 9 nM via a competitive mechanism47. Further studies have shown 
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that norendoxifen can bind to ER-α and -β with EC50 values of 27 ± 5 nM and 35 
± 17 nM, respectively48. 
As you may see, the primary metabolites of tamoxifen are likely to be 
further metabolized via demethylation or hydroxylation. Secondary metabolites 
are less likely to be further metabolized. 
 
1.8 Comparison of SERMs, SERDs and AIs for the treatment of ER-positive 
breast cancer 
Since Tamoxifen is the most widely used SERM for the treatment of ER-
positive breast cancer, we will use tamoxifen as a representative of SERMs. 
 
1.8.1 Tamoxifen versus AIs 
Many studies have shown that the use of an AI as primary adjuvant 
therapy is superior to tamoxifen for the treatment of ER-positive breast cancer in 
post-menopausal women. Compared to tamoxifen, AIs are also associated with 
fewer serious side effects49. 
A randomized clinical trial comparing tamoxifen with letrozole is the 
“Breast International Group (BIG) 1-98” trial. BIG 1-98 is a double-blind clinical 
trial involving 8010 patients randomly assigned to four treatment arms: 1) 5 years 
of tamoxifen; 2) 5 years of letrozole; 3) 2 years of tamoxifen + 3 years of 
letrozole; 4) 2 years of letrozole + 3 years of tamoxifen50,51. The results have 
shown that 5 years of letrozole significantly prolonged disease-free survival 
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(DFS), overall survival (OS) and time to distant recurrence (TDR) in comparison 
with 5 years of tamoxifen52.  
Randomized clinical trials comparing tamoxifen with anastrozole include 
the “Anastrozole, Tamoxifen Alone or in Combination (ATAC)” trial, “ARNO 95” 
trial and “ITA” trial. The ATAC trial is a double-blind clinical trial involving 9366 
subjects randomly assigned to three treatment arms: 1) 5 years of tamoxifen 
(reference arm); 2) 5 years of anastrozole (first experimental arm); 3) 5 years of 
combined tamoxifen/anastrozole (second experimental arm). The results have 
shown that 5 years of anastrozole significantly improved DFS, improved time to 
recurrence and reduced distant metastases in comparison with 5 years of 
tamoxifen53. ITA is a randomized clinical trial involving 448 patients (received 2-3 
years of adjuvant tamoxifen treatment) assigned to two treatment arms: 1) 2-3 
years of continued tamoxifen (5 years of total duration) or 2) 2-3 years of 
anastrozole (5 years of total duration). The results have shown that switching to 
anastrozole significantly prolonged DFS and time to recurrence by months. Even 
though the OS in anastrozole arm was longer than that in continued tamoxifen 
arm, the difference was not statistically significant (p-value=0.1) 54,55. ARNO 95 
(very similar to ITA) is a randomized clinical trial involving 969 patients (received 
2 years adjuvant tamoxifen treatment) assigned to 2 treatment arms: 1) 3 years 
of continued tamoxifen or 2) 3 years of anastrozole. The results have shown that 
switching to anastrozole significantly prolonged DFS, prolonged OS and reduced 
disease recurrence in comparison with continuing tamoxifen treatment56,57.  
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Randomized clinical trials comparing tamoxifen with exemestane include 
the “Intergroup Exemestane Study (IES)” trial, and “TEAM” trial. IES is a double-
blind clinical trial involving 4742 patients (received 2-3 years adjuvant tamoxifen 
treatment) randomly assigned to two treatment arms: 1) 2-3 years of continued 
tamoxifen (5 years of total duration) or 2) 2-3 years of exemestane (5 years of 
total duration). The results have shown that switching to exemestane significantly 
prolonged DFS. There was no significant difference for OS between the two 
arms58-60. TEAM is a randomized clinical trial involving 9779 patients assigned to 
two arms: 1) 5 years of exemestane or 2) 5 years of tamoxifen followed by 
exemestane. There was no significant difference for DFS between the two 
arms61. 
 
1.8.2 Tamoxifen versus fulvestrant 
The first randomized clinical trial comparing tamoxifen with fulvestrant was 
published in 200462. This trial is a double-blind clinical trial involving 587 patients 
assigned to two treatment arms: 1) fulvestrant arm or 2) tamoxifen arm with a 
median follow-up of 14.5 months. There was no significant difference for time to 
progression (TTP) between the two arms62. 
 
1.8.3 Fulvestrant versus AIs 
To date, only one AI, exemestane, was compared with fulvestrant to 
assess treatment efficacy in the clinical trials. Randomized clinical trials 
comparing fulvestrant with exemestane include the “Evaluation of Faslodex 
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versus Exemestane Clinical Trial (EFFECT)” trial and “Study of Faslodex, 
Exemestane and Arimidex (SoFEA)” trial. EFFECT is a double-blind clinical trial 
involving 693 patients randomly assigned to two treatment arms: 1) fulvestrant 
arm or 2) exemestane arm with a median follow-up of 13 months. The results 
have shown that there was no significant difference for TTP or clinical benefit 
rate between the two arms63,64. SoFEA is a randomized clinical trial involving 723 
patients assigned to three treatment arms: 1) fulvestrant + anastrozole; 2) 
fulvestrant + placebo; 3) exemestane alone. The results have shown that there 
was no significant difference for progression-free survival (PFS) between 
fulvestrant + placebo arm and exemestane alone arm65. 
 
1.9 Side effects of SERMs, SERDs and AIs for the treatment of ER-positive 
breast cancer 
The treatment effects of ER-positive breast cancer by both SERMs and 
AIs have been limited by side effects, which reduce the quality of life and 
compromise compliance. Both SERMs and AIs are associated with a number of 
side effects. Here, tamoxifen will be used as a representative of SERMs again. 
 
1.9.1 Side effects of tamoxifen 
Tamoxifen is associated with increased risks of menopausal symptoms 
(including hot flashes and atrophic vaginitis), endometrial cancer, 
thromboembolic events, gynecologic symptoms (including vaginal dryness, 
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vaginal discharge and ovarian cysts), irregular menses, ocular toxicity, 
thrombocytopenia, and leukopenia66.  
Menopausal symptoms are the most common side effects associated with 
tamoxifen, and they are more common in pre-menopausal women. Of the 
menopausal symptoms, hot flashes are the most frequent side effect affecting at 
least 50% of women taking tamoxifen. Since tamoxifen has partial estrogenic 
activity in some tissues (such as endothelium), it can increase the risk of side 
effects including endometrial cancer, endometrial hyperplasia, endometrial 
thickness, and ovarian cysts. The most serious side effect of tamoxifen is its 
potential of increasing the risk of endometrial cancer. Thromboembolic events, 
including deep venous thrombosis and pulmonary embolism, are uncommon but 
serious side effects caused by tamoxifen with an estimated incidence of 1.7% to 
8.4%67. 
Even though the partial estrogenic effects of tamoxifen increase the risk of 
side effects mentioned previously, these partial estrogenic activities prevent 
estrogen depletion which reduces the risk of other side effects, including bone 
fracture and muscle pain 68. 
 
1.9.2 Side effects of fulvestrant 
Common side effects associated with fulvestrant include gastrointestinal 
disturbances, hot flashes, ischemic cardiovascular disorder, joint disorders, 
thromboembolic events, urinary tract infection, vaginitis and weight gain69.  
25 
Interestingly, the side effects induced by fulvestrant seem very similar to 
combined side effects induced by AIs and tamoxifen, respectively. 
 
1.9.3 Side effects of AIs 
There do not appear to be any differences in safety profiles of the third 
generation AIs (letrozole, anastrozole and exemestane), even though they have 
different chemical structures and distinct modes of actions. Generally, compared 
to tamoxifen, AIs have been shown to have enhanced safety profiles with less 
increased rates of serious side effects. However, long-term adherence of AIs is 
compromised by their side effects. AIs are associated with increased risks of 
musculoskeletal symptoms (including bone loss, arthralgia and myalgia), 
menopausal symptoms (including vaginal dryness, urinary problems and sexual 
problems), hot flashes and acne 70. 
Musculoskeletal symptoms are the most undesirable side effects 
associated with AIs with an incidence rate of 36%. Among these symptoms, bone 
loss is a predictable side effect because of estrogen deprivation by AIs, while, the 
pathologies of arthralgia (joint pain) or myalgia (muscle pain) were still unknown, 
and they were thought to be due to estrogen deprivation 71.  
Adjuvant clinical trials of AIs suggested that AIs are associated with 
increased risks of menopausal symptoms (including vaginal dryness, urinary 
problems and sexual problems). The cause of sexual problems is thought to be 
multifactorial 72.  
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The mechanism of hot flashes caused by AIs is still unknown, but hot 
flashes remain a significant adverse effect in all the adjuvant clinical trials of AIs, 
with about 37% incidence rate. Even though hot flashes are not considered a 
severe side effect, long-term patient compliance may be decreased by increased 
intensity72. 
The estrogen depriving effects of AIs may disturb lipid metabolism, have 
an adverse effect on blood lipids and in turn increase the risk of cardiovascular 
diseases. Several adjuvant clinical trials of AIs have shown an increased level of 
total serum cholesterol, low-density lipoprotein (LDL) cholesterol, apolipoprotein 
B, and serum-lipid risk ratios for cardiovascular disease73. 
 
1.10 Tumor resistance to SERMs, SERDs and AIs for the treatment of ER-
positive breast cancer 
Drug resistance has been another major obstacle for the treatment effects 
of both SERMs and AIs. The efficacy and compliance of SERMs or AIs were 
comprised by both intrinsic (de novo) and acquired drug resistance. In this 
section, tamoxifen will be used as a representative for SERMs. 
 
1.10.1 Tumor resistance to tamoxifen 
About 30% of ER-positive breast cancer patients do not benefit from 
tamoxifen because of intrinsic drug resistance. In addition, those ER-positive 
breast cancer patients who initially respond to tamoxifen treatment may develop 
acquired drug resistance later. The mechanisms of resistance to tamoxifen may 
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be attributed to several aspects: 1) cytochrome P450 (CYP) enzymes; 2) loss or 
altered expressions of ERα/β; 3) phosphorylation of ERα/β; 4) alterations of co-
regulatory proteins; 5) growth factor receptor signaling pathways; 6) PI3K/AKT 
cell survival pathways. 
CYPs: since endoxifen is believed to be the most important active 
metabolite, the drug metabolizing process involved in the production of endoxifen 
is essential for tamoxifen treatment efficacy. CYP2D6 is the key CYP to 
metabolize tamoxifen to endoxifen, and single nucleotide polymorphisms (SNPs) 
of CYP2D6 can result in reduction to null enzyme activity. Also drug-drug 
interactions between tamoxifen and a CYP2D6 inhibitor will lead to a decreased 
production of active tamoxifen metabolites, which further leads to decreased 
treatment efficacy. 
Loss or altered expressions of ERα/β: since ER-α has been believed to be 
the most important target of endocrine therapy for ER-positive breast cancer, 
patients lacking ER-α expression generally do not benefit from tamoxifen 
treatment. The finding of ER-β complicated the estrogen signaling, and several 
studies have shown that reduced ER-β expression may result in resistance to 
tamoxifen74. 
Phosphorylation of ERα/β: both ER-α and ER-β are targets of 
serine/threonine/tyrosine phosphorylation, among which serine phosphorylation 
is most prevalent than the other two types. Several studies have shown that 
serine phosphorylation is more likely to lead to tamoxifen resistance75.  
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Alterations of co-regulatory proteins: as mentioned before, when 
tamoxifen binds to ERs in the breast tissue, this binding will recruit co-repressors 
leading to the suppression of estrogen-responsive gene expression. Therefore, 
the alterations in co-regulatory proteins may result in resistance to tamoxifen. For 
example, previous studies have shown that reduced expression of a co-repressor 
NCOR1 is associated with poor tamoxifen clinical response76.  
Growth factor receptor signaling pathways: many experimental facts 
suggest that growth factor receptors, such as EGFR, HER2 and IGF-R1 are 
involved in resistance to tamoxifen. It is believed that EGFR/HER2 expression 
can lead to resistance to tamoxifen in ER-positive breast cancer, and IGF-IR 
expression (dependent on ER) is associated tamoxifen resistance77. 
Overexpression of EGFR or HER2 in ER-positive breast cancer has been 
associated with drug resistance78. It has also been demonstrated that a HER2 
inhibitor, gefitinib, can improve the anti-tumor effect of tamoxifen and delay the 
acquired resistance to tamoxifen79. Another study has shown that 
phosphorylation of IGF-1R is associated with increased resistance to tamoxifen 
by interacting with EGFR and ERs on membrane. 
PI3K/AKT cell survival pathways: PI3K is usually activated in tumor cells 
by cell surface receptors kinase or G-protein-coupled receptors. PI3K can 
activate AKT, which further contributes to phosphorylation and cell survival. And, 
this activation is believed to be able to stimulate ER-β transcriptional activity and 
enhance the recruitment of co-activator80. Previous studies have also shown that 
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increased PI3K-mediated AKT activation can lead to estrogen-independent 
proliferation and resistance to tamoxifen81.  
 
1.10.2 Tumor resistance to fulvestrant 
Fulvestrant has fewer drug resistance issues in comparison with tamoxifen 
or AIs. The mechanism of fulvestrant resistance is usually attributed to growth 
factor receptor signaling pathways, including EGFR, HER2, MAPK, IGF1R and 
PI3K/AKT. Previous studies have shown that overexpression of HER2 and its 
downstream MAPK are associated with resistance to fulvestrant82. Other 
research has shown that overexpression of IGF1R is associated with the 
resistance to fulvestrant83. Very similar to tamoxifen resistance, the increased 
PI3K-mediated AKT phosphorylation can result in estrogen-independent 
proliferation and thus resistance to fulvestrant80. 
 
1.10.3 Tumor resistance to AIs 
Both intrinsic (de novo) and acquired drug resistance to AIs become a 
major obstacle for the treatment effects of AIs. The mechanisms of AIs 
resistance include: 1) pharmacological mechanisms; 2) alternative sources to 
estrogen; 3) inherent estrogen insensitivity; 4) activation of hormone signaling 
pathways; 5) cell survival pathways. 
Pharmacological mechanisms: AIs may become ineffective or 
compromised due to a decreased plasma concentration caused by drug 
metabolism or drug-drug interactions or both. For example, UDP-
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glucuronosyltransferase can deactivate and clear anastrozole and exemestane; 
therefore, the overexpression of UDP-glucuronosyltransferase may cause 
resistance to anastrozole and exemestane84. In another example, concomitant 
use of tamoxifen with anastrozole or letrozole will decrease the plasma 
concentrations of both AIs, which may lead to the ineffectiveness of AI 
treatment85,86. 
Alternative sources to estrogen: even though AIs are able to block the 
synthesis of endogenous estrogen, their effects may be compromised when 
exogenous estrogenic compounds or estrogen-similar steroids exist87. Estrogen-
similar steroids, like adrenal androgens, can interact with ERs similarly to 
estrogen. 
Inherent estrogen insensitivity: despite ER-negative breast cancer, the 
truth is that many ER-positive breast cancers are also resistant to AIs88. There 
are two possible reasons: first, ERs are mutated or aberrant or both; second, co-
regulatory proteins are mutated or aberrant or both89. 
Activation of growth factor receptor signaling pathways: this mechanism of 
resistance is the same for tamoxifen, fulvestrant and AIs, because the tumor cells 
become estrogen independent by activating growth factor receptor signaling 
pathways. As discussed before, this mechanism can be caused by 
overexpression of EGFR, HER2, MAPK, IGF1R and PI3K/AKT. 
Cell survival pathways: there has been a hypothesis that even though AIs 
can inhibit breast cancer cells growth, effective cell survival is sufficient to 
maintain overall tumor growth. 
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1.11 Combination of SERMs/SERDs and AIs for the treatment of ER-
positive breast cancer 
The hypothesis of combining anti-cancer drugs is that agents with different 
mechanism of actions and non-overlapping toxicity could be administrated 
concurrently to maximize anti-tumor effects and alleviate side effects caused by 
an agent as a monotherapy. An AI is an agent that can suppress estrogen 
production and a SERM/SERD is an agent that can antagonize estrogenic 
activity. The combination of a SERM/SERD and an AI is thought to be able to 
achieve a complete estrogen blockade. To discover synergistic effects of 
combining a SERM/SERD and an AI, both preclinical studies and clinical trials 
have been conducted to assess the efficacy and safety profiles of the 
combination of SERMs/SERDs and AIs. Previous studies have shown that the 
combination of a SERM/SERD and an AI may improve treatment efficacy and 
patients’ compliance by increasing breast cancer tumor growth inhibition, 
reducing the risk of drug resistance, and alleviating the side effects.  
 
1.11.1 Increasing treatment efficacy 
Two preclinical studies (fulvestrant + letrozole and fulvestrant + 
anastrozole in mice models) and one clinical trial (Southwest Oncology Group-
226, SWOG-226) have shown the combination of fulvestrant (a SERD) and an AI 
(letrozole and anastrozole) can increase treatment efficacy. Fulvestrant + 
letrozole in a mice model: in 2005, Dr. Brodie’s group reported a study using 
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female ovariectomized athymic mice with human ER-positive breast cancer cells 
transfected with aromatase gene (MCF-7Ca). Mice were assigned to four groups 
and treated daily with: 1) vehicle (control); 2) fulvestrant alone; 3) letrozole alone; 
4) letrozole + fulvestrant. Fulvestrant-treated tumors were unchanged for the first 
4 weeks and had doubled their initial volume after 10 weeks of treatment. 
Letrozole-treated tumors were inhibited by 40% for the first 8 weeks. However, 
these tumors slowly returned to their initial size after 17 weeks of treatment and 
had doubled after 21 weeks of treatment. Combined letrozole/fulvestrant had 
similar tumor inhibitory ability to letrozole alone in the first 8 weeks, but the 
combination was able to inhibit tumor growth by 45% after 29 weeks90. 
Fulvestrant + anastrozole in a mice model: in 2008, Dr. Brodie’s group reported 
another study using the same intratumoral aromatase mice model. Seven 
treatment arms were tested: 1) anastrozole alone; 2) fulvestrant alone; 3) 
anastrozole sequential to fulvestrant; 4) fulvestrant sequential to anastrozole; 5) 
anastrozole + fulvestrant; 6) anastrozole sequential to anastrozole + fulvestrant; 
7) fulvestrant sequential to anastrozole + fulvestrant; 8) vehicle (control). The 
combination of anastrozole and fulvestrant was the most effective treatment arm 
to inhibit tumor proliferation over time. Also, treatment arms of anastrozole or 
fulvestrant sequential to anastrozole + fulvestrant were superior to monotherapy 
anastrozole or fulvestrant or in sequence91. SWOG-226 clinical trial: a clinical trial 
involving 694 post-menopausal women with HR-positive metastatic breast cancer 
were randomly assigned (1:1 ratio) to receive anastrozole (with crossover to 
fulvestrant alone) in monotherapy group or the combination of anastrozole and 
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fulvestrant. The median progression-free survival (PFS) of the combination group 
was better than the monotherapy group (15.0 months versus 13.5 months, 
HR=0.80, p-value=0.007). The overall survival (OS) of the combination group 
was also superior to the monotherapy group (47.7 months versus 41.3 months, 
HR=0.81, p-value=0.05). Therefore, the conclusion of SWOG-226 is that the 
combination of anastrozole and fulvestrant was more effective than anastrozole 
alone or sequential anastrozole and fulvestrant for the treatment of HR-positive 
metastatic breast cancer. The incidence rate of side effects (greater than or 
equal to grade 3) were not significantly different between the two groups92.  
 
1.11.2 Delaying or halting tumor resistance 
One preclinical study (fulvestrant + anastrozole in mice model) has shown 
the combination of fulvestrant (a SERD) and an AI (anastrozole) can delay or halt 
tumor resistance to endocrine therapy. In an intratumoral aromatase mice model 
described above, anastrozole + fulvestrant from the beginning or in sequence 
could effectively down-regulate proteins involved in the development of drug 
resistance, such as insulin-like growth factor type I receptor β (IGF-IRβ), 
mitogen-activated protein kinase (MAPK), p-MAPK, AKT, mammalian target of 
rapamycin (mTOR), p-mTOR, and ER-α91. 
 
1.11.3 Alleviating side effects 
The Anastrozole, Tamoxifen Alone or in Combination (ATAC) trial has 
shown the combination of tamoxifen (a SERM) and an AI (anastrozole) can 
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alleviate side effects induced by either tamoxifen or anastrozole. In the ATAC 
trial, in comparison with anastrozole, the tamoxifen treatment is associated with 
an increased risk of endometrial cancer (0.5%) and some incidences of new 
primary cancers (0.2% melanoma); while, in comparison with tamoxifen, the 
anastrozole treatment is associated with increased risks of side effects including 
musculoskeletal disorders (27.8%), bone fractures (5.9%) and incidences of new 
primary cancers (0.8% colorectal cancer and 0.3% lung cancer). In the 
combination arm (tamoxifen + anastrozole), the rate of endometrial cancer was 
fewer than the tamoxifen arm (0.3% versus 0.5%), rate of musculoskeletal 
disorders was less than the anastrozole arm (22.1% versus 27.8%), rate of bone 
fractures was fewer than the anastrozole arm (4.6% versus 5.9%). Most 
importantly, the incidence rates of new primary cancers were lowest in the 
combination arm among the three arms (anastrozole versus tamoxifen versus 
anastrozole + tamoxifen): colorectal cancer (0.8% versus 0.6% versus 0.3%), 
lung cancer (0.3% versus 0.2% versus 0.1%), melanoma (0.0% versus 0.2% 
versus 0.0%) and overall new primary cancer (3.5% versus 3.4% versus 2.6%)93. 
The ATAC trial was designed as a five-year trail with three parallel arms, 
however, the combination arm (anastrozole + tamoxifen) was discontinued based 
on the initial analyses at 33 and 47 months of median follow-up. The initial 
analyses showed no superior therapeutic benefit of the combination arm over the 
anastrozole monotherapy arm in terms of both disease-free survival (DFS) and 
breast cancer recurrence94. However, there are three facts in the ATAC trial that 
will challenge a generalized conclusion that all SERM/AI combinations will 
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inevitably generate no additional benefit in comparison with using an AI or a 
SERM alone: 1) the pharmacokinetics (PK) of anastrozole was significantly 
affected by the co-administration of tamoxifen, with a 27% reduction in plasma 
concentration of anastrozole. Even though plasma concentration of E2 was 
similar between the combination arm and the anastrozole arm; this cannot lead 
to a conclusion that higher exposure of anastrozole will not have any contribution 
to the efficacy; 2) during a long-term treatment of tamoxifen and anastrozole, 
patients are shown to have resistance towards these medications. Development 
of resistance to a treatment is important factor that affects long-term treatment 
efficacy and patients’ compliance. With a relatively short period (33 or 47 
months), patients may have not developed resistance to anastrozole or 
tamoxifen yet, and previous studies have shown the potential of combined 
SERD/AI to delay or halt the development of resistance; 3) this result cannot be 
generalizable to all SERMs/SERDs and AIs combinations or dual AI/SERM(D) 
agents. 
 
1.12 Research objectives 
Current endocrine therapy for the treatment of ER-positive breast cancer 
such as SERMs, SERDs and AIs are associated with side effects and drug 
resistance, which compromise both treatment efficacy and patients’ compliance. 
One possible strategy to improve both treatment outcomes and patients 
compliance is to develop agents with dual AI and SERM/SERD activities. As 
shown in previous preclinical studies and clinical trials of combining an AI and a 
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SERM/SERD, the potential benefits of a dual AI/SERM(D) agent include: 1) 
increasing treatment efficacy; 2) delaying or halting development of drug 
resistance; 3) alleviating side effects caused by SERMs, SERDs or AIs. The 
previous studies by our group have shown that norendoxifen, a metabolite of 
tamoxifen, is a potent AI in vitro, and norendoxifen has high binding affinity for 
ERs (ER‐α and ‐β) in vitro. The potent aromatase inhibitory activity and the high 
binding affinity for ERs support the idea of further utilizing norendoxifen as a lead 
compound for the development of dual AI/SERM(D) agents. Moreover, the fact 
that millions of patients have already been exposed to norendoxifen as a 
metabolite of tamoxifen supports a low-risk safety profile expected for 
norendoxifen. 
The central hypothesis of this dissertation is that tamoxifen metabolites 
may possess both aromatase inhibitory and ER antagonistic activity. Studies 
outlined in this dissertation test this hypothesis through the following specific 
aims: 
Aim 1. To test the inhibitory activity and binding affinities of tamoxifen 
metabolites against aromatase and ERs (ER‐α and ‐β) in vitro. 
Aim 2. To test the cellular aromatase inhibitory activity and ERs (ER‐α and 
‐β) antagonistic activity by tamoxifen metabolites in vitro. 
Aim 3. To design, synthesize and characterize norendoxifen analogues 
with dual aromatase inhibitory activity and ER modulatory activity. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Chemical and reagents 
The E-, mixed (E,Z) and Z-norendoxifen were provided by Dr. Mark 
Cushman (Purdue University, West Lafayette, IN). The chemical makeup of the 
E-norendoxifen used in the studies is 100:1 E,Z, whereas the Z-norendoxifen is 
1:10 E,Z. They were stored at -20°C without light. Hydroxynorendoxifen was 
provided by Dr. Mark Cushman (Purdue University, West Lafayette, IN) and it 
was stored at -20°C without light. Cytochrome P450 (CYP) inhibitor screening kits 
of aromatase (CYP19), CYP1A2, CYP2A6, CYP3A4, CYP3A5, CYP2C19 and 
CYP2D6 were purchased from BD Biosciences (San Jose, CA). ERs (ER-α and -
β) competitor assay kits were purchased from Invitrogen (Carlsbad, CA). 
Minimum essential medium (MEM), HPLC-grade methanol, ethyl acetate, sodium 
hydroxide and sodium chloride were purchased from Fisher Scientific LLC. 
(Hanover Park, IL). Formic acid, glycine, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), 17β-estradiol (E2) and the internal standard 
(IS), diphenylhydantoin (DPH), were purchased from Sigma-Aldrich (St. Louis, 
MO). Distilled deionized water was obtained using Nanopure Infinity UV 
laboratory water system from Barnstead/Thermolyne (Dubuque, IA). Fetal bovine 
serum (FBS) and charcoal stripped FBS were purchased from Invitrogen 
(Carlsbad, CA).  
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2.2 Breast cancer cell line 
The cell line used in this study was MCF-7 (Michigan Cancer Foundation-
7), a human breast cancer cell line. The MCF-7 cells were provided by Dr. Todd 
Skaar (Indiana University School of Medicine, Indianapolis, IN). The cells were 
grown as monolayers in plastic flasks (25 cm2) containing MEM with 10% FBS, at 
37°C in a humidified 5% CO2 incubator. The cells were harvested with trypsin. 
The medium was changed every 72 h. 
 
2.3 High-performance liquid chromatography-tandem mass spectrometry 
(HPLC-MS/MS) 
2.3.1 Stock solutions 
A standard stock solution of hydroxynorendoxifen was prepared by 
dissolving 6.9 mg of hydroxynorendoxifen in 1837.7 μL of methanol. Two 
separate stock solutions of hydroxynorendoxifen were prepared and the 
corresponding concentrations were compared to check the accuracy of the initial 
stock solution. Sequential dilutions to 0.125, 0.25, 0.5, 1, 5 and 10 ng/mL were 
made in methanol to prepare standard solutions. A stock solution of DPH, the 
internal standard, was prepared by dissolving 10 mg of DPH in 10 mL of 
methanol and the working solution (500 ng/mL) was also prepared by diluting the 
solution with methanol. Four separate stock solutions of DPH were prepared and 
the corresponding concentrations were compared to check the accuracy of the 
initial stock solution. All the stock solutions were prepared on a free-base basis 
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and all solutions were stored at -20°C. The final biological content of the 
calibration standards was larger than 98%. 
 
2.3.2 Instrumentation and chromatographic conditions, HPLC-MS/MS 
operation conditions 
Analysis was performed on an API 2000 triple-quadrupole mass 
spectrometer (Applied Biosystem/MDS Sciex, Foster City, CA) equipped with a 
turbo ion spray source operating in the positive ionization mode, and controlled 
by Analyst software Version 1.4.1 in conjunction with Windows 2000. The HPLC 
system consists of two LC-20AB binary pumps and a SIL-20AHT UFLC auto-
sampler with a controller (Shimadzu, Columbia, MD, USA). The chromatographic 
separation was performed on a phenomenex Luna C18 column (100 mm × 2.0 
mm, 3 µm particle size) together with a phenomenex Luna C18 guard column (4 
mm × 2.0 mm) (Phenomenex, Torrance, CA, USA). The injection volume was 70 
µL for each human plasma sample. Before and after each injection, the needle 
was washed with acetonitrile/H2O (75/25, v/v). Mobile phase A consisted of 
methanol and formic acid (0.05% in water) (55/45, v/v) and mobile phase B 
consisted of methanol and formic acid (0.05% in water) (90/10, v/v) using the 
following gradient: linear gradient from 100% mobile phase A to 100% mobile 
phase B between 0.01 min and 15 minutes, then re-equilibrated to initial 
conditions (100% mobile phase A) between 15.01 min and 20 min at a consistent 
flow rate of 0.2 mL/min. Mass spectrometry optimization was achieved by 
adjusting both the instrument-dependent and compound-dependent parameters 
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for hydroxynorendoxifen in the positive ionization mode using DPH as an internal 
standard. The analytes including the internal standard were optimized at a 
source temperature of 550 °C, under unit resolution for quadrupoles 1 and 3, and 
were given a dwell time of 100 ms and a setting time of 0 ms. Optimal gas 
pressures for the analytes including the internal standard were collision gas, 4 
psi; curtain gas, 30 psi; ion source gas (1), 30 psi; ion source gas (2), 20 psi; ion 
spray voltage, 5500 V in the positive mode. Quantification was made using 
multiple reaction monitoring (MRM) in the positive mode. The MRM transitions of 
the precursor ions to selected product ions were m/z 376.260 → 44.026 for 
hydroxynorendoxifen and was m/z 256 → 167 for DPH (the internal standard). 
Additional compound-dependent mass spectrometer parameters are shown in 
Table 2. 
 
Table 2. Mass spectrometry settings for hydroxynorendoxifen (Hdn) and 
the internal standard, diphenylhydantoin (DPH)  
 RT (min) 
MW 
(amu) 
Q1 
(amu)
Q3 
(amu)
DP 
(V) 
EP 
(V) 
CEP 
(V) 
CE 
(V) 
CXP 
(V) 
Hdn 2.24 375.5 376.3 44.03 51.0 7.0 15.0 60.0 0.0 
DPH 2.35 252.3 256.0 167.0 40.0 4.0 15.0 20.0 4.0 
 
Hdn, hydroxynorendoxifen; DPH, diphenylhydantoin; RT, Retention time; MW, 
Molecular weight; DP, Declustering potential; EP, Entrance potential; CEP, Cell 
entrance potential; CE, Collision energy; CXP, Cell exit potential 
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2.3.3 Standard curve 
Triplicate standard curves were prepared daily by diluting the 
hydroxynorendoxifen stock solution using methanol. These dilutions were mixed 
with drug-free human plasma (total volume of 500 μL) to prepare the standard 
curves. The triplicate diluted concentrations for standard curves of 
hydroxynorendoxifen were 0.125, 0.25, 0.5, 1, 5 and 10 ng/mL. Three inter-day 
standard curves were prepared to test for intra- and inter-day variability. 
 
2.3.4 Assay accuracy and precision 
Intra- and inter-day accuracy and precision were assessed. Triplicate 
standard curves were prepared each day (3 independent days) and assayed. 
The concentration of each hydroxynorendoxifen standard was estimated using 
the standard curve run on the same day. An average (± SD) of each 
hydroxynorendoxifen standard was calculated and used to estimate accuracy 
and precision. Accuracy (%) was calculated by the following equation: Accuracy 
(%) = 100% - 100% × (standard concentration – estimated concentration) / 
standard concentration. Precision, expressed as the coefficient of variation (CV), 
was estimated by the following equation: CV (%) = 100% × (SD of estimated 
concentrations / average of estimated concentrations) 42. 
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2.3.5 Extraction efficiency 
Triplicate non-extracted samples containing the same concentrations of 
hydroxynorendoxifen with the internal standard, DPH, were injected into the 
HPLC. An average of these samples at each concentration was designated as 
the 100% extracted sample. Then, triplicate hydroxynorendoxifen samples of 
each concentration with the internal standard were prepared, extracted and 
injected into the HPLC. The peak area ratio of hydroxynorendoxifen to the 
internal standard was compared to that of the non-extracted sample to estimate 
the extraction efficiency. The average (± SD) extraction efficiency of triplicate 
samples was reported for each concentration (0.125, 0.25, 0.5, 1, 5 and 10 
ng/mL) in standard curves. 
 
2.3.6 Extraction procedure for calibration standards 
For calibration standards, 450 μL of drug-free human plasma with a known 
concentration of hydroxynorendoxifen was placed into clean 13-mL screw-cap 
glass tubes. After adding 25 μL of the internal standard solution (500 ng/mL DPH 
in methanol) into each tube, the mixture was made alkaline by adding 1 mL of 1 
M NaOH-glycine buffer (pH=11.3) and vortex-mixed. The 1 M NaOH-glycine 
buffer (pH=11.3) was prepared by mixing equal volumes of 1 M glycine solution 
and 1 M NaCl solution. The pH of the buffer was adjusted to 11.3 by adding 1 M 
NaOH solution. Ethyl acetate (6 mL) was added to each sample. The mixture 
was mixed on a shaker for 15 minutes and centrifuged for 15 minutes at 3600 g. 
Then the organic phase was extracted. The organic phase was transferred to a 
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13 mm × 100 mm glass culture tube and evaporated to dryness. The residue was 
reconstituted using 160 μL of mobile phase A and a 70 μL aliquot was then 
injected into the HPLC column.  
2.3.7 Analysis of patient plasma samples 
Plasma samples from breast cancer patients who had been treated with 
20 mg daily oral dosage of tamoxifen for 4 months were analyzed. The patient 
enrollment criteria, clinical trial design and sampling schedule have been 
described in detail in a previous publication95. Plasma samples of patients 
analyzed herein were obtained after 4 months of treatment with tamoxifen. The 
study was approved by the Institutional Review Board of Indiana University and 
each patient signed informed consent statements before participation. The 
plasma samples were extracted and processed as described above. 
 
2.4 Aromatase inhibition assay 
2.4.1 Inhibition of recombinant human CYP isoforms by microsomal 
incubations 
The activity of each recombinant human CYP isoform was determined by 
measuring the conversion rate of a fluorometric substrate to its fluorescent 
metabolite. The activity of aromatase (CYP19) was determined using the 
metabolism of 7-methoxy-4-trifluoromethylcoumarin (MFC) to 7-hydroxy-4-
trifluoromethylcoumarin (HFC). The activities of CYP1A2 and CYP2C19 were 
determined using the metabolism of 3-cyano-7-ethoxycoumarin (CEC) to 3-
cyano-7-hydroxycoumarin (CHC). The activity of CYP2A6 was determined using 
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the metabolism of coumarin to 7-hydroxycoumarin (HC). The activities of 
CYP3A4 and CYP3A5 were determined using the metabolism of 7-benzyloxy-4-
trifluoromethyl-coumarin (BFC) to 7-hydroxy-4-trifluoromethylcoumarin (HFC). 
Experimental procedures were essentially as described previously 96. All of the 
incubations were performed using incubation times and protein concentrations 
that were within the linear range for the reaction velocity. All the substrates were 
dissolved in acetonitrile (25 mM final concentration for MFC, 20 mM final 
concentration for CEC, 1.1 mM final concentration for coumarin and 50 mM final 
concentration for BFC). E- and mixed norendoxifen were dissolved in 
methanol/dichloromethane (1:1, v/v, 10 mM final concentration stock) . Z-
Norendoxifen and hydroxynorendoxifen was dissolved in methanol (10 mM final 
concentration stock). During serial dilutions, all the E-, mixed, Z-norendoxifen 
and hydroxynorendoxifen were diluted in methanol to required concentrations. A 
series of concentrations of E-, mixed, Z-norendoxifen and hydroxynorendoxifen 
in a volume of 2 µL were mixed with 98 µL of NADPH-Cofactor Mix (16.25 µM 
NADP+, 825 µM MgCl2, 825 µM glucose-6-phosphate and 0.4 Units/mL glucose-
6-phosphate dehydrogenase) and were pre-warmed for 10 minutes at 37°C. The 
enzyme/substrate mix was prepared with fluorometric substrate, recombinant 
human CYP isoforms and 0.1 M potassium phosphate buffer (pH 7.4). Reactions 
were initiated by adding 100 µL enzyme/substrate mix to bring the incubation 
volume to 200 µL and incubated for 30 minutes. All the reactions were stopped 
by adding 75 µL of 0.1 M Tris base dissolved in acetonitrile. The amount of 
fluorescent product was determined immediately by measuring fluorescent 
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response using a BioTek (Winooski, VT) Synergy 2 fluorometric plate reader. 
Excitation-emission wavelengths for MFC metabolite and BFC metabolite were 
409-530 nm, for CEC metabolite were 410-460 nm, for coumarin metabolite were 
390-460 nm. Standard curves were constructed using the appropriate fluorescent 
metabolite standards. Quantification of samples was performed by applying the 
linear regression equation of the standard curve to the fluorescence response. 
The limits of quantification for the metabolites of MFC, CEC, coumarin and BFC 
were 24.7 pmol, 66.7 pmol, 74.1 pmol and 222.2 pmol in a final volume of 200 
µL, respectively, with intra- and inter-assay coefficients of variations less than 
10%. 
 
2.4.2 Kinetic analysis of recombinant human CYP isoforms 
The rates of metabolite formation in the presence of test inhibitors were 
compared with those in the control incubation, in which the inhibitor was replaced 
with vehicle. The extent of enzyme inhibition was expressed as a percentage of 
remaining enzyme activity compared to the control. The IC50 was determined as 
the inhibitor concentration which brought about a 50% reduction in enzyme 
activity by fitting all the data to a one-site competition equation using GraphPad 
Prism 5.0 (GraphPad Software Inc., San Diego, CA). To characterize the 
inhibitory mechanism of norendoxifen against aromatase (CYP19), CYP1A2, 
CYP2A6, CYP3A4, CYP3A5, CYP2C19 and CYP2D6, all inhibitory data of 
norendoxifen at different substrate concentrations were plotted as Lineweaver-
Burk, Eadie-Hofstee and Dixon plots. The inhibitory constant Ki values were 
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determined by nonlinear least square regression analysis using GraphPad Prism 
5.0 (GraphPad Software Inc., San Diego, CA). Before modeling the data using 
nonlinear models, initial information about the inhibitory mechanism was obtained 
by visual inspection of Lineweaver-Burk, Eadie-Hofstee and Dixon plots. Final 
decisions on the mechanism of inhibition were made on model-derived 
parameters, such as R2 (or R Square) and absolute sum of squares. 
 
2.5 Estrogen receptor binding assay 
The binding affinity for estrogen receptor-α and -β (ER-α and ER-β) was 
determined by measuring the change of polarization value when the fluorescent 
estrogen ligand, ES2, was displaced by test compounds. Experimental 
procedures were essentially as described previously 48. The fluorescent estrogen 
ligand, ES2, was provided in methanol/water (4:1, v/v) with a concentration of 
1800 nM. Recombinant human ERs (ER-α and ER-β) were provided in buffer (50 
mM bis-tris propane, 400 mM KCl, 2 mM DTT, 1 mM EDTA, and 10% glycerol), 
with the concentration of 734 nM and 3800 nM, respectively. The test 
compounds, including E-, mixed, Z-norendoxifen and hydroxynorendoxifen, were 
dissolved in methanol. The sample solutions (1 μL) were mixed well with 49 μL of 
ES2 screening buffer (100 mM potassium phosphate, 100 μg/mL BGG, and 
0.02% NaN3). The ER-α/ES2 complex was prepared with the fluorescent 
estrogen ligand ES2, human recombinant ER-α, and ES2 screening buffer with 
the concentration of 9 nM ES2 and 30 nM ER-α. The ER-β/ES2 complex was 
prepared with the fluorescent estrogen ligand ES2, human recombinant ER-β, 
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and ES2 screening buffer with the concentration of 9 nM ES2 and 20 nM ER-β. 
Reactions were initiated by adding 50 μL of ER/ES2 complex to bring the 
incubation volume to 100 μL and incubated for 2 h avoiding light. The polarization 
value was determined by measuring fluorescent response using a BioTek 
(Winooski, VT) Synergy 2 fluorometric plate reader. Excitation−emission 
wavelengths for fluorescence polarization were 485−530 nm. The polarization 
value in the presence of the test competitors were compared with those in control 
in which the competitor was replaced with vehicle. The extent of competition was 
expressed as a percentage of the remaining polarization compared to the control. 
EC50 values were determined as the competitor concentrations which brought 
about half reduction in polarization value by fitting all the data to a one-site 
competition equation using GraphPad Prism 5.0 (GraphPad Software Inc., San 
Diego, CA). 
 
2.6 Tritiated water assay 
Aromatase activity in MCF-7 cells was measured using the tritiated water 
release assay, based on the formation of tritiated water from the aromatization of 
a labeled androgenic substrate 1β-3H(N)-androst-4-ene-3,17-dione (NET-926; 
PerkinElmer, Boston, MA) 97,98. MCF-7 cells are seeded into a 12-well plate at 
500,000 cells per well with MEM supplemented with 10% FBS. When a 
homogeneous monolayer of preconfluent MCF-7 cells was reached on days 48 h 
of the experiment, media were aspirated and replaced by FBS free media for 30 
minutes incubation. Various concentrations of norendoxifen and 
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hydroxynorendoxifen were dissolved in methanol and the final concentration of 
methanol was 0.1%. Then the FBS free media was aspired and the MCF-7 cells 
were treated with various concentrations of norendoxifen or hydroxynorendoxifen 
(12 concentrations on a logarithmic scale from 0.56 nM to 100000 nM) in 1 mL 
FBS free media containing 40 nM 1β-3H(N)-androst-4-ene-3,17-dione with a 
specific activity of 25.5 Ci/mmol and vehicle (0.1% methanol). After 4 h 
incubation at 37°C in an atmosphere containing 5% CO2, the reaction mixture 
was removed and extracted with two volumes of chloroform to terminate the 
reaction and to extract the unused substrate and steroids. After vortexing the 
solution for 15 minutes, the supernatant was centrifuged at 3000 g for 15 
minutes. Then the resulting aqueous supernatant was absorbed with an equal 
volume of 10% dextran-coated charcoal and vortexed for 15 minutes to eliminate 
the residual steroids. After 15 minutes centrifugation at 3000 g, the aqueous 
phase was added into 10 mL scintillation cocktail. Incubations in the absence of 
cells were included as negative controls, the amount of radioactivity in tritiated 
water [3H] was corrected by subtracting the blank values from each sample99. 
 
2.7 Gene expression analysis using real-time polymerase chain reaction 
(PCR) 
2.7.1 Ribonucleic acid (RNA) extraction and concentration measurement 
MCF-7 cells were seeded at a density of 5000 cells/well in 96-well plates 
with MEM containing 10% FBS and allowed to attach for 24 h. Before 
experimental treatments, these cells were preconditioned in MEM containing 
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10% charcoal stripped FBS for 3 days to remove the estrogens. Then the MCF-7 
cells treated with test compounds or experimental controls for 24 h were 
harvested for progesterone receptor (PGR) messenger ribonucleic acid (mRNA) 
extraction. Before ribonucleic acid (RNA) extraction, genomic DNA was 
eliminated. RNA was extracted from approximately 3×105 cells by RNeasy Plus 
Mini Kit (Qiagen Inc., Valencia, California, USA). The RNA concentration was 
measured using the Qubit RNA BR assay (Life Technologies Corp., Carlsbad, 
CA) for the Qubit 2.0 fluorometer (Life Technologies Corp., Carlsbad, CA). The 
RNA was stored at -80°C before further use. 
 
2.7.2 Complementary deoxyribonucleic acid (cDNA) synthesis 
Complementary deoxyribonucleic acid (cDNA) for the real-time 
quantitative polymerase chain reaction (PCR) assay was synthesized from 
DNase-treated total RNA using the QuantiTect reverse transcription kit (Qiagen 
Inc., Valencia, California, USA). 
 
2.7.3 Real-time quantitative polymerase chain reaction (PCR) for cDNA 
The cDNA was amplified with TaqMan Universal PCR Master Mix (Applied 
Biosystems Inc., Carlsbad, CA), then PCR was performed in the QuantStudio 
12K Flex Real-Time PCR System (Life Technologies Corp., Carlsbad, CA). 
Progesterone receptor (PGR, FAM, Hs01556702, Life Technologies Corp., 
Carlsbad, CA) gene was the target gene, while glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH, VIC, Hs02758991, Life Technologies Corp., Carlsbad, 
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CA) gene expression was quantified to normalize each sample. A total of 40 
amplification cycles were performed. Quantitative values of amplification were 
obtained from the threshold cycle (Ct) defined as the cycle number at which the 
fluorescent signal is first recorded above the background and is determined 
during the exponential phase of PCR rather than at the endpoint. The 2-∆∆Ct 
method was used to determine the relative mRNA expression, and the results 
were expressed as percentages of antagonistic effects compared to E2-
stimulated PGR mRNA expression (considered as 100%). If amplification was 
not seen within 40 cycles, the measured RNA was considered to be undetected. 
 
2.8 Cell proliferation assay 
The anti-proliferation effect of norendoxifen and hydroxynorendoxifen on 
breast cancer cells (MCF-7 cells) was tested using MTT cell proliferation assay. 
MCF-7 cells were seeded at a density of 5000 cells/well in 96-well plates with 
MEM containing 10% FBS and allowed to attach for 24 h. Before the 
experimental treatments, these cells were preconditioned in MEM containing 
10% charcoal stripped FBS for 3 days to remove the estrogens. Various 
concentrations of norendoxifen and hydroxynorendoxifen were dissolved in 
methanol and the final concentration of methanol was less than 0.1%. The MCF-
7 cells were treated with various concentrations of norendoxifen or 
hydroxynorendoxifen (8 concentrations on a logarithmic scale from 0.15 nM to 
2500 nM) in the presence of 1 nM β-estradiol or vehicle (0.1% methanol). 
Treatment with 1 nM β-estradiol alone was used as positive controls and 
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treatment with endoxifen was used as negative controls for 48 h39. Following 
these treatments, the MCF-7 cells were treated with 20 μL of 5 mg/mL MTT 
solution dissolved in PBS and incubated at 37°C for 4 h to allow MTT 
metabolization. The medium containing MTT was then removed and the 
precipitated crystals were dissolved by adding 150 μL/well acidic isopropylic 
alcohol (0.04 N HCl). Absorbance was measured at 540 nm using a BioTek 
(Winooski, VT) Synergy 2 fluorometric plate reader. Each experiment was carried 
out with three independent experiments. Efficiency of test compounds was 
assessed by plotting cell viability versus test compound concentration (on a log 
scale) into competition equation using GraphPad Prism 5.0 (GraphPad Software 
Inc., San Diego, CA). The IG50 value is expressed as mean standard deviation of 
three determinations, in which each concentration group contains six replicates. 
Data were analyzed using student’s t-test with statistical significance of P < 0.05. 
 
2.9 Subjects 
Eligible pre- and post-menopausal women (older than 18 years old) with 
diagnosed breast cancer were recruited from the Simon Cancer Center at 
Indiana University School of Medicine, from Lombardi Comprehensive Cancer 
Center at Georgetown University Medical Center and from the Breast Oncology 
Program at University of Michigan Comprehensive Cancer Center. Women were 
excluded from the study if they had received cytotoxic chemotherapy or adjuvant 
radiation therapy or if they had taken any hormonal therapy other than tamoxifen. 
These patients were permitted to take vitamin E, selective serotonin reuptake 
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inhibitors (SSRIs) or herbal remedies; however, they were excluded if they were 
receiving chronic corticosteroid therapy or using clonidine, bellergal or megestrol 
acetate for the treatment of hot flashes. Women were also excluded if they were 
pregnant or lactating. The study protocol was approved by the institutional review 
boards of all the three participating study sites. All the enrolled patients provided 
written informed consent before study entry. 
 
2.10 Trial Design 
All the patients were administrated with Tamoxifen orally 20 mg per day 
for 12 months and were followed up on an outpatient basis at 1, 4, 8, and 12 
months after the start of tamoxifen therapy. The patient’s blood samples (5 mL) 
were collected in heparinized tubes and the plasma of blood collection was 
separated with 1 hour using centrifugation at 2060 g. All the plasma and whole 
blood samples were transferred to cryogenic vials (Corning, Cambridge, MA) and 
shipped to the Division of Clinical Pharmacology at Indiana University School of 
Medicine on dry ice and were stored at -80°C. We picked up 10 plasma samples 
randomly from the initial 4 months of tamoxifen therapy to measure the plasma 
concentration of hydroxynorendoxifen. This time period was selected because 
tamoxifen serum concentrations have already reached steady state by 4 months 
and the confounding effects of concomitant medication usage and premature trial 
discontinuation would be limited for more possibility. 
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CHAPTER 3: AROMATASE INHIBITORY ACTIVITY AND ESTROGEN 
RECEPTOR BINDING AFFINITY OF TAMOXIFEN METABOLITES IN 
VITRO 
3.1 Introduction 
Previous studies by our group have shown that norendoxifen can inhibit 
recombinant aromatase (CYP19) via a competitive mechanism with an IC50 of 90 
nM. Further studies have shown that norendoxifen can bind to ER-α and -β with 
EC50 values of 26.9 ± 4.8 nM and 35.2 ± 16.8 nM, respectively48. 
Aromatase is a member of cytochrome P450 (CYP) superfamily, which 
consists aromatase (CYP19), CYP1A2, CYP2A6, CYP3A4, CYP3A5, CYP2B6, 
CYP2C9, CYP2C19 and CYP2D6. The selectivity of inhibitory ability of 
norendoxifen against CYP1A2, CYP2A6, CYP3A4 and CYP3A5 has not been 
described, and it follows that further studies are required to determine the effects 
of norendoxifen on these CYPs. This is important to further develop norendoxifen 
as a drug or a lead compound. The double bond in norendoxifen leads to E- and 
Z-isomers, which may possess different inhibitory activities against CYPs due to 
their different chemical structures.  
Our collaborating chemical group in Purdue University headed by Dr. Mark 
Cushman has succeeded in synthesizing the E- and Z-isomers of norendoxifen48. 
The chemical structures of E-and Z-isomers of norendoxifen are shown in Figure 
2. 
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Figure 2. Chemical structures of E- and Z- norendoxifen 
 
Hydroxynorendoxifen (N,N-didesmethyl-4,4’-dihydroxytamoxifen) is a 
derivative of norendoxifen, which is under preclinical development as dual 
SERM/AI agent for the treatment of estrogen-related conditions. Aromatase 
(CYP19), CYP1A2, CYP2A6, CYP3A4, CYP3A5 and CYP2D6 are important 
components of CYP superfamily, so further studies are required to determine the 
potency and specificity of hydroxynorendoxifen on aromatase inhibition.  
In this chapter, we will focus on Aim 1 to test the inhibitory activity and 
binding affinity of tamoxifen metabolites against aromatase and ERs (ER‐α and ‐
β) in vitro. Studies outlined in Aim 1 test this hypothesis through the following 
specific sub-aims: 
Aim 1A. To identify a novel tamoxifen metabolite in patients taking 
tamoxifen.  
Aim 1B. To test the potency and selectivity of aromatase inhibition by 
norendoxifen and hydroxynorendoxifen in vitro. 
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Aim 1C. To characterize ER binding affinity of norendoxifen and 
hydroxynorendoxifen in vitro. 
 
3.2 Results 
3.2.1 Hydroxynorendoxifen as a novel tamoxifen metabolite in patients 
taking tamoxifen 
3.2.1.1 Chromatography 
Hydroxynorendoxifen exhibited good solubility in methanol, but was less 
soluble in water. Starting from mobile phase A containing 55% methanol to 
mobile phase B containing 100% methanol, hydroxynorendoxifen showed good 
chromatography with baseline resolution. Figure 3 shows representative 
chromatograms of extracted drug-free human plasma (Figure 3A), a human 
plasma standard containing 10 ng/mL hydroxynorendoxifen (Figure 3B), a human 
plasma sample obtained from a subject after oral administration of 20 mg 
tamoxifen per day for 4 months (Figure 3C) and a human plasma standard 
containing 500 ng/mL DPH as internal standard (Figure 3D), respectively. The 
retention times for hydroxynorendoxifen and the internal standard, DPH, were 
2.24 min and 2.35 min, respectively. Comparison of drug-free human plasma 
(Figure 3A) with human plasma spiked with hydroxynorendoxifen (Figure 3B), or 
the internal standard (Figure 3D), indicated that there is no endogenous source 
of interference at or near the retention times of hydroxynorendoxifen or the 
internal standard. Similarly, no interfering peaks were observed in the 
chromatograms of patient plasma samples (which were obtained during the 
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administration of a 20 mg daily oral dose of tamoxifen for 4 months). DPH was a 
suitable internal standard for this assay because it was stable, with a relatively 
short retention time and appropriate peak shape.  
 
Figure 3. Representative chromatograms of extracted samples 
HN
NH
O
O
diphenylhydantoin (DPH)
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(A) drug-free human plasma (B) human plasma standard containing 10 ng/mL 
hydroxynorendoxifen (C) human plasma obtained from a subject after 
administration of a 20 mg daily oral dose of tamoxifen for 4 months (D) human 
plasma standard containing 500 ng/mL internal standard, diphenylhydantoin 
(DPH). 
 
3.2.1.2 Linearity 
The standard curves for hydroxynorendoxifen were constructed by 
injecting standard concentrations of hydroxynorendoxifen into the HPLC-MS/MS. 
The linear regression calibration curves based on seven points were constructed 
for hydroxynorendoxifen by plotting the peak area ratio of hydroxynorendoxifen to 
the internal standard, DPH, versus the concentrations of human plasma 
hydroxynorendoxifen standards. A typical linear regression equation for 
hydroxynorendoxifen included a slope of 0.002 and a y-intercept of 0.000. The 
calibration curves were consistently linear from 0.125 to 10 ng/mL for 
hydroxynorendoxifen.  
 
3.2.1.3 Extraction efficiency 
The extraction efficiency of hydroxynorendoxifen from human plasma was 
obtained by comparing the extracted standards to non-extracted standards. The 
extraction efficiency of hydroxynorendoxifen was greater than 86% at each 
concentration with a mean value (± SD) 91.0 ± 2.7% (Table 3). The high 
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extraction efficiency indicates there was little to no degradation of 
hydroxynorendoxifen during the extraction procedure. 
Table 3. Extraction efficiency (%) of hydroxynorendoxifen in human plasma 
Hydroxynorendoxifen (ng/mL) Extraction efficiency (%) 
0.125 93.8 ± 6.9 
0.25 91.5 ± 2.5 
0.5 93.9 ± 3.8 
1 90.7 ± 2.6 
5 89.2 ± 8.9 
10 86.9 ± 6.0 
Average ± SD 91.0 ± 2.7 
 
3.2.1.4 Assay accuracy and precision 
Triplicate standards in human plasma were extracted and analyzed to 
assess the intra-day variability of this method. Accuracy and precision (coefficient 
of variations, CVs) of hydroxynorendoxifen throughout the standard curves are 
shown in Table 4. The results showed that the intra-day accuracy ranged from 
94.2% to 107.7% and the inter-day accuracy ranged from 99.2 to 103.3%. Intra-
day CVs were less than 10% (range: 0.9-9.9%) for all the hydroxynorendoxifen 
standards over the range of concentrations tested (from 0.125 to 10 ng/mL). 
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Human plasma samples containing 0.125-10 ng/mL of hydroxynorendoxifen were 
extracted and analyzed daily to determine inter-day variability. As shown in Table 
4, inter-day CVs were also less than 10% (range: 1.4-9.5%) for all the 
hydroxynorendoxifen standards over a range of concentrations (from 0.125 to 10 
ng/mL). 
Table 4. Intra-day and inter-day accuracy and precision (coefficient of 
variations, CVs) of hydroxynorendoxifen 
Theoretical 
Concentratio
n (ng/mL) 
Intra-day Inter-day 
Estimated 
conc. 
(ng/mL) 
Accuracy 
(%) 
CVs 
(%) 
Estimated 
conc. 
(ng/mL) 
Accuracy 
(%) 
CVs 
(%) 
0.125 0.13 ± 0.01 107.0 7.9 0.13 ± 0.01 102.9 6.4 
0.25 0.26 ± 0.02 104.1 8.8 0.26 ± 0.01 103.3 1.2 
0.5 0.54 ± 0.01 107.7 2.7 0.50 ± 0.04 100.8 8.4 
1 0.94 ± 0.09 94.2 9.9 1.00 ± 0.09 99.7 9.5 
5 5.09 ± 0.16 101.8 3.0 5.02 ± 0.24 100.3 4.8 
10 10.00 ± 0.09 100.0 0.9 9.92 ± 0.14 99.2 1.4 
 
3.2.1.5 Limit of blank (LOB), limit of detection (LOD) and lower limit of 
quantification (LLOQ) 
The limit of blank (LOB) and limit of detection (LOD) for this assay method 
were determined using the standard method described in guideline EP17 of the 
Clinical and Laboratory Standards Institute (CLSI) 100. The limit of blank (LOB) is 
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defined as the highest apparent analyte concentration expected to be found, 
when replicates of drug-free human plasma (blank samples) are tested. LOB is 
estimated by calculating the mean value and the standard deviation of blank 
samples (SD blank), which is according to LOB = mean blank + 1.645 × (SD blank). 
For this assay method, the LOB was 0.0092 ng/mL. The limit of detection (LOD) 
is the lowest analyte concentration likely to be reliably distinguished from the 
LOB and at which concentration the detection is feasible. LOD was determined 
by utilizing both LOB and triplicates of 0.125 ng/mL hydroxynorendoxifen 
standards (the low concentration standard samples), which is according to LOD = 
LOB + 1.645 × (SD low concentration samples). For this assay method, the LOD was 
0.0202 ng/mL. When the lowest standard concentration was 0.125 ng/mL, the 
signal-to-noise ratio was 5.5. The intra- and inter-day CVs for 
hydroxynorendoxifen at the concentration of 0.125 ng/mL were 7.88% and 
6.37%, respectively. Therefore, concentrations of hydroxynorendoxifen in human 
plasma larger than 0.125 ng/mL can not only be efficiently detected, they can 
also be protected from bias and imprecision using this method. Since the 
observed bias and imprecision at the lowest sample concentration (0.125 ng/mL) 
meet the requirements for total error for hydroxynorendoxifen with acceptable 
accuracy and precision, the lower limit of quantification (LLOQ) for this assay 
method was the lowest calibration standard concentration of 
hydroxynorendoxifen, which is 0.125 ng/mL. The linearity obtained and the LLOQ 
determined (0.125 ng/mL) are appropriate to allow successful measurement of 
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human plasma concentrations of hydroxynorendoxifen, the metabolite of 
tamoxifen, in a prospective clinical trial of tamoxifen administration. 
 
3.2.1.6 Stability of hydroxynorendoxifen in methanol 
A solution of 10 μM hydroxynorendoxifen in methanol was frozen at -20°C 
and then thawed and assayed on 3 different days within one week. Stability of 
hydroxynorendoxifen stock solution after being stored at -20°C for 3 months and 
its stability in the auto sampler over 24 h pending to analysis were evaluated. All 
the CVs were less than 10%, and no change was observed with regard to the 
ratio of hydroxynorendoxifen to the internal standard, DPH, due to storage. 
 
3.2.1.7 Pharmacokinetic study (plasma concentration of 
hydroxynorendoxifen) 
The freeze-thaw plasma was determined over two cycles within 5 days, 
which shows no change regarding the peak area ratio of hydroxynorendoxifen to 
DPH (internal standard). This method was applied to a clinical study of 10 
women who were taking tamoxifen orally (20 mg/day) for the treatment of breast 
cancer for one year. The plasma concentrations of hydroxynorendoxifen, the 
novel metabolite of tamoxifen, quantified in these patients at 4 months are 
illustrated in Table 5 and Figure 4.  
Table 5. Plasma concentrations of hydroxynorendoxifen in 10 women after 
oral administration of 20 mg tamoxifen per day for 4 months 
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Sample id 
Concentration of 
hydroxynorendoxifen 
(ng/mL) 
Concentration of 
hydroxynorendoxifen 
(nM) 
1809-035-04 0.289 0.770 
1809-032-04 0.368 0.980 
1809-030-04 0.284 0.756 
1809-010-04 0.182 0.485 
1809-028-04 0.277 0.738 
1809-024-04 0.284 0.756 
1809-022-04 0.452 1.204 
1809-027-04 0.336 0.895 
1809-006-04 0.359 0.956 
1809-042-04 0.239 0.637 
Average ± SD 0.307 ± 0.075 0.817 ± 0.200 
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Figure 4. Plasma concentrations of hydroxynorendoxifen in 10 breast 
cancer patients plasma samples 
These samples were collected from 10 patients, who took oral administration of 
20 mg/day tamoxifen for the treatment of breast cancer. The cross bar 
represents the median concentration of hydroxynorendoxifen in this patients 
plasma. 
 
3.2.2 Potency and selectivity of aromatase inhibition by norendoxifen and 
hydroxynorendoxifen in vitro 
The IC50 and Ki values of important tamoxifen metabolites against 
aromatase (CYP19) were shown in Table 6. Norendoxifen (E,Z) can inhibit 
aromatase with a Ki value of 70 ± 9 nM. Hydroxynorendoxifen (E,Z) was a more 
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potent aromatase inhibitor (AI) with a Ki value of 20 ± 4 nM. N-DMT and 
endoxifen were very weak AIs with Ki values larger than 1000 nM, while, 4-HT 
and tamoxifen itself did not show any aromatase inhibitory activity. 
Table 6. IC50 and Ki values of important tamoxifen metabolites against 
aromatase (CYP19) 
 IC50 (nM) against aromatase (CYP19) 
Ki (nM) against 
aromatase (CYP19) 
Tamoxifen N.A. N.A. 
N-DMT 20700 15900 
4-HT N.A. N.A. 
Endoxifen 6100 4000 
Norendoxifen 131 ± 54 70 ± 9 
Hydroxynorendoxifen 45 ± 3 20 ± 4 
 
N.A. = Not Active 
 
To test the selectivity of norendoxifen (E,Z) against aromatase (CYP19), 
the inhibition of CYPs by norendoxifen, including aromatase (CYP19), CYP1A2, 
CYP2A6, CYP3A4, CYP3A5 and CYP2C19, were tested using microsomal 
incubations. Figure 5 showed the inhibitory potency of norendoxifen (E,Z) against 
CYP enzymes. Norendoxifen can inhibit recombinant CYP2C19, aromatase 
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(CYP19), CYP1A2, CYP3A4, CYP3A5 and CYP2A6 with Ki values of 2.80 ± 0.29 
nM, 131 ± 54 nM, 207 ± 26 nM, 285 ± 81 nM, 723 ± 27 nM and 6373 ± 983 nM, 
respectively. Norendoxifen showed significantly different inhibitory activity against 
CYP2C19 when CEC was used as a substrate, compared to that seen when R-
omeprazole was used. In the previous studies by our group, the inhibition of 
CYP2C19 activity by norendoxifen in HLMs using R-omeprazole as a substrate 
was very weak, with <25% enzyme activity reduced when the concentration of 
norendoxifen was 5 μM. Our findings indicated that norendoxifen may have 
substrate-dependent inhibition, and further study on the inhibition of CYP2C19 by 
tamoxifen metabolites should be conducted.  
Figure 6 shows the dixon plots of inhibition of CYP1A2, CYP2A6, 
CYP3A4, CYP3A5 and CYP2C19 by norendoxifen (E,Z). Norendoxifen inhibited 
aromatase (CYP19), CYP1A2, CYP2A6 and CYP2C19 via a competitive 
mechanism, while norendoxifen inhibited CYP3A4 and CYP3A5 via a 
noncompetitive mechanism.  
 
  
66 
 
Figure 5. Inhibition of cytochrome P450 enzymes by norendoxifen (E,Z). 
In the presence of a range of concentrations of norendoxifen (E,Z), the remaining 
enzyme activity of recombinant aromatase (CYP19) (●), CYP1A2 (■), CYP2A6 
(▲), CYP3A4 (▼), CYP3A5 (◆) and CYP2C19 (○) were determined by 
measuring the conversion rates from specific fluorometric substrates to their 
fluorescent metabolites. The extent of enzyme inhibition was expressed as 
percentage of remaining enzyme activity compared to the control. Each point 
represents the mean of four independent incubations and error bars represent 
the standard deviations of 4 independent points. 
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Figure 6. Dixon plots of inhibition of CYP1A2, CYP2A6, CYP3A4, CYP3A5 
and CYP2C19 by norendoxifen (E,Z) 
(A) CEC (2.5 to 10 μM) was incubated with 2.5 nM recombinant CYP1A2 in the 
presence of increasing norendoxifen concentrations (0 to 90 nM). (B) Coumarin 
(3 to 7 μM) was incubated with 5 nM recombinant CYP2A6 in the presence of 
increasing norendoxifen concentrations (0 to 11 μM). (C) BFC (25 to 100 μM) 
was incubated with 5 nM recombinant CYP3A4 in the presence of increasing 
norendoxifen concentrations (0 to 1600 nM). (D) BFC (25 to 100 μM) was 
incubated with 5 nM recombinant CYP3A5 in the presence of increasing 
norendoxifen concentrations (0 to 1150 nM). (E) CEC (10 to 75 μM) was 
incubated with 5 nM recombinant CYP2C19 in the presence of increasing 
norendoxifen concentrations (0 to 4 nM). Each point represents one incubation, 
and two independent incubations were conducted for each concentration of 
norendoxifen and substrate. 
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Similarly, the inhibition of CYPs by hydroxynorendoxifen (E,Z) was tested 
using microsomal incubations to determine the inhibitory specificity of 
hydroxynorendoxifen against aromatase (CYP19) and understand whether the 
inhibitory ability extends to other important CYPs. Figure 7 showed the inhibitory 
activity of hydroxynorendoxifen against human recombinant CYP2C19, 
aromatase (CYP19), CYP1A2, CYP2A6, CYP3A4, CYP3A5 and CYP2D6. 
Hydroxynorendoxifen is able to inhibit these recombinant CYPs with IC50 values 
of 2.10 ± 0.35 nM, 45 ± 3 nM, 207 ± 56 nM, 6730 ± 659 nM, 1884 ± 336 nM, 556 
± 52 nM and 3597 ± 395 nM, respectively.  
Figure 8 shows the dixon plots of inhibition of these enzymes by 
hydroxynorendoxifen (E,Z). Hydroxynorendoxifen inhibits aromatase (CYP19), 
CYP1A2, CYP2A6 and CYP2D6 via a competitive mechanism with Ki values of 
20 ± 4 nM, 56 ± 5 nM, 710 ± 212 nM and 423 ± 124 nM, respectively. 
Hydroxynorendoxifen inhibits CYP3A4 and CYP3A5 via a noncompetitive 
mechanism with Ki values of 1635 ± 89 nM and 855 ± 14 nM, respectively.  
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Figure 7. Inhibition of cytochrome P450 enzymes by hydroxynorendoxifen 
(E,Z) 
In the presence of a range of concentrations of hydroxynorendoxifen (E,Z), the 
remaining enzyme activity of recombinant aromatase (CYP19) (●), CYP1A2 (■), 
CYP2A6 (▲), CYP3A4 (▼), CYP3A5 (◆), CYP2D6 (○) and CYP2C19 (+) were 
determined by measuring the conversion rates from specific fluorometric 
substrates to their fluorescent metabolites. The extent of enzyme inhibition was 
expressed as a percentage of remaining enzyme activity compared to the 
control. Each point represents the mean of four independent incubations and 
error bars represent the standard deviations of four independent determinations. 
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Figure 8. Dixon plots of inhibition of aromatase (CYP19), CYP1A2, CYP2A6, 
CYP3A4, CYP3A5, CYP2D6 and CYP2C19 by hydroxynorendoxifen (E,Z) 
(A) MFC (25 to 50 μM) was incubated with 7.5 nM recombinant aromatase 
(CYP19) in the presence of increasing hydroxynorendoxifen concentrations (0 to 
130 nM). (B) CEC (1 to 10 μM) was incubated with 2.5 nM recombinant CYP1A2 
in the presence of increasing hydroxynorendoxifen concentrations (0 to 800 nM). 
(C) Coumarin (1.5 to 9 μM) was incubated with 5 nM recombinant CYP2A6 in the 
presence of increasing hydroxynorendoxifen concentrations (0 to 15 μM). (D) 
BFC (10 to 100 μM) was incubated with 5 nM recombinant CYP3A4 in the 
presence of increasing hydroxynorendoxifen concentrations (0 to 3200 nM). (E) 
BFC (25 to 100 μM) was incubated with 5 nM recombinant CYP3A5 in the 
presence of increasing hydroxynorendoxifen concentrations (0 to 900 nM). (F) 
AMMC (0.5 to 4.5 μM) was incubated with 7.5 nM recombinant CYP2D6 in the 
presence of increasing hydroxynorendoxifen concentrations (0 to 6 μM). (G) CEC 
(10 to 75 μM) was incubated with 5 nM recombinant CYP2C19 in the presence of 
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increasing hydroxynorendoxifen concentrations (0 to 4 nM). Each point 
represents the mean of two independent incubations. 
 
IC50 and Ki values of norendoxifen (E,Z) and hydroxynorendoxifen (E,Z) 
against important CYPs are shown in Table 7.  
Table 7. IC50 and Ki values of norendoxifen (E,Z) and hydroxynorendoxifen 
(E,Z) against important cytochrome P450 enzymes 
Important 
CYPs 
Norendoxifen Hydroxynorendoxifen 
IC
50
 
(nM) 
K
i
 (nM) Inhibitory 
mechanism 
IC
50
 
(nM) 
K
i
 (nM) Inhibitory 
mechanism 
Recombinant 
CYP19 
(aromatase) 
131 ± 
54 70 ± 9 Competitive 45 ± 3 20 ± 4 Competitive 
Recombinant 
CYP1A2 
207 ± 
26 76 ± 3 Competitive 
207 ± 
56 56 ± 5 Competitive 
Recombinant 
CYP2A6 
6373 ± 
983 
2176 ± 
256 Competitive 
6730 ± 
659 
710 ± 
212 Competitive 
Recombinant 
CYP3A4 
285 ± 
81 375 ± 6
Non-
competitive 
1884 ± 
336 
1635 ± 
89 
Non-
competitive 
Recombinant 
CYP3A5 
723± 
27 
829 ± 
62 
Non-
competitive 
556 ± 
52 
855 ± 
14 
Non-
competitive 
Recombinant 
CYP2C19 
2.80 ± 
0.29 
0.56 ± 
0.02 Competitive 
2.10 ± 
0.35 
0.64 ± 
0.11 Competitive 
Recombinant 
CYP2D6 N.A. N.A. N.A. 
3597 ± 
395 
423 ± 
124 Competitive 
Recombinant 
CYP2B6 N.A. N.A. N.A. N.A. N.A. N.A. 
 
CYPs, cytochrome P450 enzymes 
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To explore and determine the isomers’ selective effects of norendoxifen 
against CYPs, the inhibitory activities of E- and Z-norendoxifen against human 
recombinant aromatase (CYP19), CYP1A2, CYP3A4, CYP3A5 and CYP2C19 
were further tested in the same way using microsomal incubations (Table 8, 
Figure 9). The IC50 values of E- and Z-norendoxifen against recombinant 
aromatase (CYP19) were 98 ± 40 nM and 1053 ± 185 nM, respectively (Figure 
9A). While the IC50 values of E- and Z-norendoxifen against recombinant 
CYP1A2 were 160 ± 22 nM and 285 ± 43 nM, respectively (Figure 9B). The IC50 
values of E- and Z-norendoxifen against recombinant CYP3A4 were 182 ± 79 nM 
and 925 ± 145 nM, respectively (Figure 9C). The IC50 values of E- and Z-
norendoxifen against recombinant CYP3A5 were 930 ± 66 nM and 655 ± 27 nM, 
respectively (Figure 9D). The IC50 values of E- and Z-norendoxifen against 
recombinant CYP2C19 were 1.90 ± 0.35 nM and 3.88 ± 0.79 nM, respectively 
(Figure 9E).  
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Figure 9. Inhibition of aromatase (CYP19), CYP1A2, CYP3A4, CYP3A5 and 
CYP2C19 by E- and Z-norendoxifen. 
(A) The remaining enzyme activity of recombinant aromatase (CYP19) in the 
presence of a range of concentrations of E-norendoxifen (●) and Z-norendoxifen 
(◆) were determined by measuring the formation rates from MFC to HFC. (B) 
The remaining enzyme activity of recombinant CYP1A2 in the presence of a 
range of concentrations of E-norendoxifen (●) and Z-norendoxifen (◆) were 
determined by measuring the formation rates from CEC to CHC. (C) The 
remaining enzyme activity of recombinant CYP3A4 in the presence of a range of 
concentrations of E-norendoxifen (●) and Z-norendoxifen (◆) were determined 
by measuring the formation rates from BFC to HFC. (D) The remaining enzyme 
activity of recombinant CYP3A5 in the presence of a range of concentrations of 
E-norendoxifen (●) and Z-norendoxifen (◆) were determined by measuring the 
formation rates from BFC to HFC. (E) The remaining enzyme activity of 
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recombinant CYP2C19 in the presence of a range of concentrations of E-
norendoxifen (●) and Z-norendoxifen (◆) were determined by measuring the 
formation rates from CEC to CHC. Each point represents the mean of four 
independent incubations and error bars represent the standard deviations of four 
independent points. 
Table 8. IC50 and Ki values of E- and Z-norendoxifen against important 
cytochrome P450 enzymes 
CYPs 
IC50 Ki 
E-
Norendoxifen
Z-
Norendoxifen
E-
Norendoxifen 
Z-
Norendoxifen
Recombinant 
CYP19 
(aromatase) 
98 ± 40 1053 ± 185 48 ± 3 445 ± 6 
Recombinant 
CYP1A2 160 ± 22 285 ± 43 49 ± 3 96 ± 8 
Recombinant 
CYP3A4 182 ± 79 925 ± 145 242 ± 9 910 ± 59 
Recombinant 
CYP3A5 930 ± 66 655 ± 27 859 ± 76 707 ± 17 
Recombinant 
CYP2C19 1.90 ± 0.35 3.88 ± 0.79 0.48 ± 0.05 0.70 ± 0.11 
 
CYPs, cytochrome P450 enzymes 
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3.2.3 ER binding affinity of norendoxifen (E,Z) and hydroxynorendoxifen 
(E,Z) in vitro 
The EC50 values of important tamoxifen metabolites to ERs (ER-α and ER-
β) are shown in Table 9. Norendoxifen (E,Z) can bind to ERs with EC50 values of 
27 ± 5 nM and 35 ± 17 nM, respectively. Hydroxynorendoxifen (E,Z) has higher 
binding affinity with EC50 values of 19 ± 8 nM and 11 ± 2 nM, respectively. 
 
Table 9. EC50 values of important tamoxifen metabolites to ERs (ER-α and 
ER-β) 
 Binding affinity (EC50, nM) for ER-α 
Binding affinity (EC50, 
nM) for ER-β 
Tamoxifen 60.9 188 
N-DMT N.A. N.A. 
4-HT 29.6 26.1 
Endoxifen 28.2 30.5 
Norendoxifen 27 ± 5 35 ± 17 
Hydroxynorendoxifen 19 ± 8 11 ± 2 
 
N.A. = Not Active 
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3.3 Discussion 
Results summary for chapter 3 (aromatase inhibitory activity and estrogen 
receptor binding affinity of tamoxifen metabolites in vitro): 
1) Hydroxynorendoxifen is a novel metabolite of tamoxifen, with an average 
plasma concentration of 0.82 nM (0.31 ng/mL) in patients taking 20 
mg/day tamoxifen after 4 months. 
2) Norendoxifen and hydroxynorendoxifen are potent aromatase inhibitors 
(AIs), with Ki values of 70 nM and 20 nM, respectively. 
3) Norendoxifen and hydroxynorendoxifen are relatively selective for 
aromatase inhibition. The order of inhibitory potency of norendoxifen 
against important CYPs were human recombinant CYP2C19 > aromatase 
(CYP19) > CYP1A2 > CYP3A4 > CYP3A5 > CYP2A6. The order of 
inhibitory potency of hydroxynorendoxifen against important CYPs were 
human recombinant CYP2C19 > aromatase (CYP19) > CYP1A2 > 
CYP2D6 > CYP2A6 > CYP3A5 > CYP3A4. 
4) Norendoxifen and hydroxynorendoxifen have high binding affinity against 
ER‐α and ER‐β, with EC50 values less than 35 nM. In comparison with 4-
HT or endoxifen, norendoxifen had similar binding affinity to ERs and 
hydroxynorendoxifen had even higher binding affinity to ERs in vitro. 
5) Norendoxifen has high isomer selectivity against human recombinant 
aromatase (CYP19). E-Norendoxifen had 9.3-fold higher inhibitory ability 
than Z-norendoxifen against aromatase (CYP19). E-Norendoxifen 
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inhibited CYP1A2 and CYP3A4 2.0-fold and 3.7-fold, respectively, more 
potently than Z-norendoxifen. 
As hydroxynorendoxifen was identified as a novel metabolite of tamoxifen, 
HPLC-MS/MS method will be required to characterize hydroxynorendoxifen 
during both preclinical and clinical pharmacokinetic (PK) studies. The method 
presented here describes a sensitive and reproducible human PK assay to 
identify and quantify hydroxynorendoxifen, a novel metabolite of tamoxifen, using 
HPLC-MS/MS. The method should make it possible to conduct detailed PK and 
PD studies of tamoxifen and hydroxynorendoxifen, which will allow better 
understanding of the contribution of hydroxynorendoxifen to the anti-cancer 
activity of tamoxifen and will allow further development of this dual SERM/AI 
agent, an important step towards development of this class of compounds as 
clinical treatments for breast cancer and estrogen-related conditions. 
Tamoxifen is extensively metabolized in humans, involving both active and 
inactive metabolites via various oxidative and conjugated routs, in which 
cytochrome P450 enzymes played dominant roles in the metabolism of 
tamoxifen101. It has been believed that the clinical response of tamoxifen for the 
treatment of breast cancer results from a series of effects from its different active 
metabolites, which contribute to high binding affinity to the ER and 
agonist/antagonist profiles102. The metabolism of tamoxifen results in two main 
metabolites, N-desmethyl tamoxifen (N-DMT) and 4-hydroxytamoxifen (4-HT) via 
CYP3A4 and CYP2D6, respectively. Endoxifen is mainly produced via CYP2D6-
mediated hydroxylation of N-DMT and via CYP3A4-mediated N-demethylation of 
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4-HT103. Among the tamoxifen metabolites, 4-HT and endoxifen have been 
shown to bind to ERs with similar affinity and have ER antagonistic activity40. 
However, since the mean steady-state plasma concentration of endoxifen is 5 to 
7 times higher than that of 4-HT, endoxifen is believed to be the most important 
active metabolite of tamoxifen as an anti-breast cancer pro-drug104. Studies have 
shown that the tissue concentrations of endoxifen are higher, appearing to be 10-
100 times more than plasma concentrations of endoxifen105. N-DMT and 
endoxifen can inhibit human recombinant aromatase (CYP19) with IC50 values of 
6.1 µM and 20.7 µM in vitro, respectively106. Figure 10 describes the possible 
metabolic pathway involved in the production of hydroxynorendoxifen from 
tamoxifen based on in vitro studies. 
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Figure 10. Possible metabolic pathway involved in the production of 
hydroxynorendoxifen from tamoxifen 
The metabolism of tamoxifen results in two main metabolites, N-desmethyl-
tamoxifen (N-DMT) and 4-hydroxytamoxifen (4-HT). Both N-DMT and 4-HT are 
converted into endoxifen, a minor metabolite. Endoxifen is demethylated to 
norendoxifen, after which hydroxynorendoxifen is formed by hydroxylation of 
norendoxifen. 
 
In this work, aromatase inhibitory activity of hydroxynorendoxifen was 
tested using microsomal incubations. Hydroxynorendoxifen has more potent 
aromatase inhibitory activity than norendoxifen in vitro with a Ki value of 20 ± 4 
nM. As shown in Table 10, the ratios of tamoxifen metabolites and their 
corresponding Ki values ([I]/Ki) were calculated. Typically, when [I]/Ki is larger 
than 0.1, the inhibitory effects would be considered significant. Our data resulted 
in [I]/Ki values of 0.03, 0.04 and 0.04 for N-DMT, norendoxifen and 
hydroxynorendoxifen, respectively. Even though these values did not reach the 
0.1 criteria, previous studies have shown that the tissue concentrations of 
tamoxifen metabolites are higher, appearing to be 10-100 times more than 
plasma concentrations of tamoxifen metabolites. Therefore, the potent 
aromatase inhibitory activity of norendoxifen or hydroxynorendoxifen should not 
be ignored due to the potential higher level of these metabolites produced by 
higher tissue tamoxifen concentrations. These results emphasize that the 
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contributions of aromatase inhibitory activity of N-DMT and endoxifen should be 
also considered to be clinical effects of tamoxifen. 
 
Table 10. Average plasma concentrations of tamoxifen metabolites divided 
by corresponding Ki values against aromatase (CYP19) 
 
Average 
plasma 
concentration 
(nM) 
Average Ki 
(nM) against 
aromatase 
(CYP19) 
[I]/Ki (average 
plasma 
concentration/Ki)
Tamoxifen 372.5 N.A. N.A. 
N-DMT 653.4 20700 0.03 
4-HT 9.5 N.A. N.A. 
Endoxifen 78.0 6100 0.01 
Norendoxifen 3 70 0.04 
Hydroxynorendoxifen 0.817 20 0.04 
 
N.A. = Not Active 
 
Previous studies in our group have characterized the inhibitory ability of 
norendoxifen against human recombinant aromatase (CYP19), CYP2B6, 
CYP2D6, human liver CYP2C9 and CYP2C19. Other members of the CYP 
superfamily, including CYP1A2, CYP2A6, CYP3A4 and CYP3A5, also play 
important roles. In human liver, CYP1A2 accounts for 13% of the CYP content 
and catalyzes the primary metabolic route for a number of important drugs, 
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including caffeine, clozapine, flutamide, lidocaine, olanzapine and zolmitriptan25. 
CYP2A6 is a major CYP in human liver, specifically involved in the oxidative 
metabolism of nicotine. It is also involved in the metabolism of pharmaceutical 
agents such as methoxyflurane, halothane, losigamone, letrozole, valproic acid, 
disulfiram and fadrozole26,27. CYP3A4 and CYP3A5 account for about 50% of the 
CYP content and are the predominant CYP contributors to metabolism in human 
liver, accounting for 40-60% of the oxidative metabolism of marketed drugs28.  
Any proposed new drug that undergoes significant metabolism by CYP 
superfamily should be evaluated for CYPs inhibition and further for drug-drug 
interactions (DDIs). In this work, we tested inhibition of important CYPs by 
norendoxifen and hydroxynorendoxifen. The results show that both norendoxifen 
and hydroxynorendoxifen are relatively selective for aromatase (CYP19) 
inhibition. 
Since both norendoxifen and hydroxynorendoxifen share similar chemical 
structures with endoxifen, it is possible that they can function as SERMs. In this 
context, the binding affinity of norendoxifen and hydroxynorendoxifen for ERs 
was conducted using microsomal incubations. In comparison with 4-HT or 
endoxifen, norendoxifen had similar binding affinity for ERs and 
hydroxynorendoxifen had even higher binding affinity for ERs in vitro.  
As minor metabolites of tamoxifen, norendoxifen and hydroxynorendoxifen 
turn out to be the most potent AIs and possess the highest binding affinity for 
ERs among all the known metabolites that we have tested in vitro. Our results 
reveal a complex metabolism of tamoxifen that may lead to some metabolites 
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that are able to act as AIs or act as SERMs or dual SERM/AI agents. Since the 
concentration of norendoxifen and hydroxynorendoxifen in the tissues may be 
higher, as demonstrated with endoxifen, it may significantly increase the clinical 
activity of tamoxifen in vivo, due to its potent inhibitory ability against CYP19 and 
high binding affinity for ERs. 
To explore and determine the isomer selective effects of norendoxifen 
against CYP enzymes, studies were conducted on testing the inhibitory activity of 
E- and Z-norendoxifen against human recombinant aromatase (CYP19), 
CYP1A2, CYP3A4, CYP3A5 and CYP2C19. Norendoxifen has high isomer 
selectivity against aromatase (CYP19). E-Norendoxifen had 9.3-fold higher 
inhibitory ability than Z-Norendoxifen against aromatase (CYP19). E-
Norendoxifen inhibited CYP1A2 and CYP3A4 2.0-fold and 3.7-fold, respectively, 
more potently than Z-norendoxifen. E- and Z-norendoxifen had similar inhibitory 
ability against CYP3A5 and CYP2C19. The double bond of norendoxifen does 
have a significant impact on the inhibitory activities of its E- and Z-isomers 
against aromatase (CYP19). The high selectivity of E-norendoxifen also provides 
new information for the development of potent AIs. While the main form of 
norendoxifen as the metabolite of tamoxifen in human body is the Z-isomer, the 
toxicity and metabolism of the E-norendoxifen deserve more study. 
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CHAPTER 4: CELLULAR AROMATASE INHIBITORY ACTIVITY AND 
ESTROGEN RECEPTOR ANTAGONISTIC ABILITY OF NORENDOXIFEN 
AND HYDROXYNORENDOXIFEN 
4.1 Introduction 
Norendoxifen and hydroxynorendoxifen have been considered new 
classes of SERMs or AIs or dual SERM/AI agents under development, therefore, 
they should be evaluated for cellular aromatase inhibitory activity, ER-responsive 
gene expression antagonistic activity and anti-proliferation activity against breast 
cancer cells. These assays would become strong assets to characterize 
aromatase inhibitory activity and antagonistic activity of both norendoxifen and 
hydroxynorendoxifen against breast cancer cells. 
In this chapter, we will focus on Aim 2 to test the cellular aromatase 
inhibitory activity and antagonistic activity against ERs (ER‐α and ‐β) by 
tamoxifen metabolites in vitro. Studies outlined in Aim 2 test this hypothesis 
through the following specific sub-aims: 
Aim 2A. To test the cellular aromatase inhibitory activity by norendoxifen 
and hydroxynorendoxifen. 
Aim 2B. To test activity of norendoxifen and hydroxynorendoxifen to 
antagonize ER-responsive gene expression (in estradiol-stimulated breast 
cancer cells).  
Aim 2C. To test anti-proliferation activity of norendoxifen and 
hydroxynorendoxifen against breast cancer cells (stimulated by estradiol). 
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4.2 Results 
4.2.1 Cellular aromatase activity inhibition by norendoxifen and 
hydroxynorendoxifen 
As shown in Figure 11, norendoxifen (E,Z) and hydroxynorendoxifen (E,Z) 
can inhibit cellular aromatase activity in MCF-7 cells with IC50 values of 565 ± 
111 nM and 282 ± 68 nM, respectively.  
 
 
Figure 11. Inhibition of cellular aromatase activity in MCF-7 cells by 
norendoxifen (E,Z) and hydroxynorendoxifen (E,Z) 
In the presence of a range of concentrations of norendoxifen (E,Z) and 
hydroxynorendoxifen (E,Z), the remaining aromatase activity in MCF-7 cells were 
determined using the tritiated water assay. The extent of enzyme inhibition was 
expressed as a percentage of remaining enzyme activity compared to the 
control. Each point represents the mean of four independent incubations and 
error bars represent the standard deviations of four independent determinations. 
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4.2.2 Activity of norendoxifen and hydroxynorendoxifen to antagonize ER-
responsive gene expression (in E2-stimulated breast cancer cells) 
To assess their antagonistic transcriptional activity in the presence of E2, 
norendoxifen (E,Z) and hydroxynorendoxifen (E,Z) were tested on the MCF-7 
cells at a concentration of 1 μM dissolved in minimum essential media (MEM) 
supplemented with 10% charcoal-stripped fetal bovine serum (FBS). As shown in 
Figure 12 (each result was expressed as mean ± SD), the presence of 10 nM E2 
was able to significantly increase the mRNA expression of progesterone receptor 
(PGR) gene compared to the control, which only contained 0.1% methanol 
(vehicle) in MEM supplemented with 10% charcoal-stripped FBS. PGR mRNA 
expression level with 10 nM E2 stimulation alone was considered as 100% PGR 
mRNA expression. Endoxifen was used as a positive control as it can antagonize 
PGR mRNA expression in the presence of 10 nM E2 to 10% expression level 
compared to 10 nM E2 stimulation alone, which is consistent with the previous 
published results40. Norendoxifen and hydroxynorendoxifen were able to 
antagonize PGR mRNA expression level to 32% and 14%, respectively. All the 
test compounds have shown statistically significant difference compared to the 
E2 alone stimulated control. 
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Figure 12. Activity of norendoxifen and hydroxynorendoxifen to antagonize 
progesterone receptor (PGR) mRNA expression in MCF-7 cells 
MCF-7 cells were treated with 1000 nM norendoxifen and hydroxynorendoxifen 
in the presence of 10 nM 17β-estradiol (E2). PGR mRNA expression level with 
10 nM E2 stimulation alone was considered as 100% PGR mRNA expression. 
Treatment with 1000 nM endoxifen was used as a positive control. Data 
represent mean ± standard deviations from three independent determinations. 
 
4.2.3 Anti-proliferation activity of norendoxifen and hydroxynorendoxifen 
against breast cancer cells (stimulated by estradiol) 
The anti-proliferative effect of norendoxifen and hydroxynorendoxifen on 
human breast cancer cells (MCF-7 cells) was measured by MTT assay. As 
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shown in Figure 13, the presence of 1 nM 17β-estradiol (E2) was able to 
significantly increase the proliferation of MCF-7 cells compared to the controls, 
which only contained 0.1% methanol (vehicle) in MEM supplemented with 10% 
charcoal-stripped FBS. In the presence of norendoxifen or hydroxynorendoxifen, 
the growth of MCF-7 cells was inhibited, and the IG50 (inhibiting growth by 50%) 
values of norendoxifen and hydroxynorendoxifen on MCF-7 cells were 25 ± 12 
nM and 9 ± 3 nM, respectively. 
 
 
Figure 13. Anti-proliferative effects of norendoxifen (E,Z) and 
hydroxynorendoxifen (E,Z) on human breast cancer cells 
Human breast cancer cells (MCF-7 cells) viability was measured by MTT assay. 
To determine the anti-proliferative effect of norendoxifen (E,Z) and 
hydroxynorendoxifen (E,Z), MCF-7 cells were treated with different 
concentrations of norendoxifen (E,Z) and hydroxynorendoxifen (E,Z) in the 
presence of 1 nM 17β-estradiol (E2). Treatment of E2 alone and vehicle alone 
were used as controls, respectively. Data represent the mean ± standard 
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deviations from three independent determinations, in each of which every 
concentration group contains six replicates with one assay.  
 
4.3 Discussion 
Results summary for chapter 4 (cellular aromatase inhibitory activity and 
ER antagonistic ability of norendoxifen and hydroxynorendoxifen): 
1) Norendoxifen and hydroxynorendoxifen can inhibit cellular aromatase 
activity in MCF-7 cells with IC50 of 565 nM and 282 nM, respectively. 
2) Norendoxifen and hydroxynorendoxifen can inhibit breast cancer cell 
proliferation with IG50 of 25 nM and 9 nM, respectively. 
3) Norendoxifen and hydroxynorendoxifen can suppress progesterone 
receptor (PGR) gene mRNA expression level by reducing 68% and 86% 
PGR mRNA expression. 
In this chapter, more work on cellular aromatase inhibition was done to 
confirm the aromatase inhibitory activity of norendoxifen and 
hydroxynorendoxifen. The results are consistent with our previous findings using 
human recombinant aromatase (CYP19) that hydroxynorendoxifen is a more 
potent AI than norendoxifen. Table 11 shows the IC50 values of norendoxifen and 
hydroxynorendoxifen against aromatase using two methods, and the ratios of 
IC50 values (cellular/recombinant aromatase inhibition) were also calculated. 
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Table 11. IC50 values of norendoxifen (E,Z) and hydroxynorendoxifen (E,Z) 
against cellular and recombinant aromatase activity 
 Norendoxifen Hydroxynorendoxifen
Cellular aromatase 
inhibition (IC50, nM) 
565 282 
Recombinant 
aromatase inhibition 
(IC50, nM) 
131 45 
Ratio 
(cellular/recombinant 
aromatase inhibition) 
4.3 6.3 
 
The IC50 values of norendoxifen and hydroxynorendoxifen against cellular 
aromatase are higher than those of recombinant aromatase. There might be 
three reasons leading to the difference: 1) these compounds have to cross the 
cell membrane to inhibit the aromatase activity; 2) efflux drug transporter on the 
cell membrane may pump these compounds out; 3) even though cofactor 
proteins have been incorporated into the microsomal incubations when testing 
hum recombinant aromatase inhibition, however, there may be some other 
cofactor proteins existing in the MCF-7 cells leading to binding of norendoxifen 
and hydroxynorendoxifen. Also, it is notable that the ratio of cellular/recombinant 
aromatase inhibition for hydroxynorendoxifen was higher than that for 
norendoxifen (6.3 fold for hydroxynorendoxifen versus 4.3 fold for norendoxifen), 
which may be caused by many reasons, such as cell membrane permeability due 
to the increased hydrophobic nature of hydroxynorendoxifen, compound stability, 
and protein binding. 
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According to previous studies (ATAC, IES, BIG-98), the third generation 
AIs (letrozole, anastrozole and exemestane) are superior to tamoxifen as drugs 
to reduce the recurrence of ER-positive breast cancer in post-menopausal 
women. However, their efficacy is compromised by toxicities that reduce quality 
of life and treatment adherence107,108. Obviously, new AIs with fewer side effects 
are needed to allow better treatment of ER-positive breast cancer in post-
menopausal women. As we discussed previously, several studies have shown 
that the combination of a SERM/SERD agent and an AI have the potential to 
increase breast cancer tumor growth inhibition, reduce the risk of drug 
resistance, and alleviate side effects. 
The results show that both norendoxifen and hydroxynorendoxifen 
possess dual SERM(D)/AI activity, and they can become attractive lead 
compounds for the development of dual SERM(D)/AI agents because of three 
unique features: 1) the potent inhibitory ability of norendoxifen and 
hydroxynorendoxifen are able to reduce estrogen biosynthesis in the breast to 
inhibit the tumor growth, while, its ER antagonistic activity make it possible to 
completely deplete the E2 effects; 2) since norendoxifen and 
hydroxynorendoxifen are metabolites of the most widely used SERM, tamoxifen, 
lots of patients have already been exposed to them supports a low-risk safety 
profile expected for norendoxifen and hydroxynorendoxifen; 3) since 
norendoxifen and hydroxynorendoxifen share the similar chemical structures with 
endoxifen and tamoxifen, they may have agonistic activity in some tissues, such 
as bone tissue. In this way, norendoxifen and hydroxynorendoxifen may 
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ameliorate some side effects in bone and other tissues caused by estrogen 
depletion. 
The data reveal a complex metabolism of tamoxifen that may lead to 
some metabolites that are able to inhibit aromatase (CYP19) or act as a SERM 
or combine both of these activities. Also, the contribution of norendoxifen to the 
overall effects of tamoxifen remains unknown and its concentration in patients is 
not well defined. Studies have shown that endoxifen has low concentration in 
plasma, however, the tissue concentrations of endoxifen are higher, appearing to 
be 10 -100 times more105. The tissue concentration of norendoxifen may be 
higher, as demonstrated with endoxifen. Since norendoxifen has potent inhibitory 
ability against aromatase (CYP19), it may significantly increase the effects of 
tamoxifen in vivo. All of these possibilities deserve more study and are important 
for better understanding of tamoxifen function and novel drug development for 
the treatment of breast cancer. 
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CHAPTER 5: CHARACTERIZATION OF NORENDOXIFEN ANALOGUES 
WITH DUAL AROMATASE INHIBITORY ABILITY AND ESTROGEN 
RECEPTOR ANTAGONISITIC ACTIVITY 
5.1 Introduction 
Previous studies by our group discovered that norendoxifen was a 
compound with dual aromatase inhibitory and ER antagonistic activity. To 
improve the efficacy and develop more lead compounds, 87 structurally related 
norendoxifen analogues were synthesized by Dr. Wei Lv, Dr. Liming Zhao, Dr. 
Elizaveta N O'Neill and Dr. Mark Cushman from our collaborating group at 
Purdue University. Figure 14 showed the chemical structures of the norendoxifen 
analogues. 
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Figure 14. Chemical structures of norendoxifen analogues 
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In this chapter, we will focus on Aim 3 to characterize norendoxifen 
analogues with dual aromatase inhibitory activity and estrogen receptor 
antagonistic activity. Studies outlined in Aim 3 test this hypothesis through the 
following specific sub-aims: 
Aim 3A. To test the potency of aromatase inhibition by norendoxifen 
analogues in vitro. 
Aim 3B. To characterize ER binding affinities of norendoxifen analogues 
in vitro. 
Aim 3C. To test ER antagonistic activity of norendoxifen analogues in 
vitro. 
 
5.2 Results 
5.2.1 Potency of aromatase inhibition and ER binding affinity by 
norendoxifen analogues in vitro 
The IC50 values of lead norendoxifen analogues against aromatase 
(CYP19) and the EC50 values of lead norendoxifen analogues to ERs (ER-α and 
ER-β) are shown in Table 12 (values less than 500 nM were highlighted in red). 
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Table 12. IC50 values of lead norendoxifen analogues against aromatase 
(CYP19) and the EC50 values of lead compounds to ERs (ER-α and ER-β) 
Compounds 
IC50 (nM) against 
Aromatase 
(CYP19) 
EC50 (nM) for 
ER-α binding 
affinity 
EC50 (nM) for 
ER-β binding 
affinity 
WL-IV-4 156 ± 1 N.A. N.A. 
WL-IV-79 9194 ± 67 147 ± 4 20 ± 7 
WL-IV-73 N.A. 311 ± 44 69 ± 7 
WL-V-52 4.8 ± 0.4 27 ± 5 41 ± 12 
WL-V-24 53 ± 2 274 ± 44 181 ± 82 
WL-V-33 1240 ± 176 35 ± 11 21 ± 6 
WL-V-3 143 ± 2 265 ± 7 52 ± 22 
WL-V-76BT1 715 ± 10 57 ± 11 48 ± 25 
WL-V-76BB2 699 ± 63 176 ± 54 58 ± 33 
WL-V-65 49 ± 12 N.A. N.A. 
WL-V-58 137 ± 6 N.A. N.A. 
WL-V-54 7339 ± 449 27 ± 15 13 ± 1 
WL-V-80 48 ± 8 144 ± 62 50 ± 9 
WL-V-79 17 ± 1 N.A. N.A. 
WL-V-76top 174 ± 10 290 ± 194 519 ± 345 
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WL-V-74 1017 ± 295 88 ± 6 49 ± 13 
WL-V-61 337 ± 13 675 ± 458 28 ± 19 
WL-VI-22 261 ± 40 384 ± 161 36 ± 9 
WL-VI-13 328 ± 53 N.A. N.A. 
WL-VI-28 493 ± 29 3176 ± 243 1346 ± 550 
WL-VI-77 5.2 ± 0.4 1826 ± 910 296 ± 154 
WL-VI-41 60 ± 4 98 ± 42 74 ± 30 
WL-VI-79but 18 ± 1 N.A. N.A. 
WL-VI-79top 104 ± 10 N.A. N.A. 
WL-VI-75 36 ± 1 N.A. N.A. 
WL-7-1 94 ± 4 85 ± 14 56 ± 18 
ZHAO-I-20 221 ± 42 213 ± 54 486 ± 239 
ZHAO-I-28 62 ± 8 72 ± 43 70 ± 5 
ZHAO-I-39 230 ± 11 11036 ± 828 857 ± 389 
ZHAO-I-46 177 ± 20 N.A. N.A. 
ZHAO-I-44 9 ± 2 1711 ± 630 1263 ± 423 
ZHAO-I-42 13 ± 3 N.A N.A. 
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ZHAO-I-50 287 ± 32 451 ± 201 346 ± 115 
ZHAO-I-51 645 ± 246 164 ± 97 218 ± 102 
EO-34 60 ± 2 N.A. N.A. 
 
Among the 87 norendoxifen analogues, 13 compounds (WL-V-52, WL-V-
24, WL-V-3, WL-V-80, WL-V-76top, WL-V-61, WL-VI-22, WL-VI-77, WL-VI-41, 
WL-7-1, ZHAO-I-20, ZHAO-I-28 and ZHAO-I-50) had both potent aromatase 
inhibitory activity and high ERs binding affinity with IC50 and EC50 values less 
than 500 nM. 
Among the 87 norendoxifen analogues, 14 compounds (WL-IV-4, WL-V-
65, WL-V-58, WL-V-79, WL-VI-13, WL-VI-28, WL-VI-79but, WL-VI-79top, WL-VI-
75, ZHAO-I-39, ZHAO-I-46, ZHAO-I-44, ZHAO-I-42 and EO-34) had only potent 
aromatase inhibitory activity with IC50 values less than 500 nM. 
 Among the 87 norendoxifen analogues, 8 compounds (WL-IV-79, WL-IV-
73, WL-V-33, WL-V-76BT1, WL-V-76BB2, WL-V-54, WL-V-74 and ZHAO-I-51) 
had only high ERs binding affinity with EC50 values less than 500 nM. 
 
5.2.2 ER antagonistic activity of norendoxifen analogues in vitro 
To assess the antagonistic transcriptional activity of norendoxifen 
analogues in the presence of 17β-estradiol (E2), 18 norendoxifen analogues 
were tested on MCF-7 cells at a concentration of 1 μM dissolved in minimum 
essential media (MEM) supplemented with 10% charcoal-stripped fetal bovine 
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serum (FBS). The reason for choosing these 18 compounds is that they have 
relatively high ER binding affinities for ER-α or ER-β or both. As shown in Figure 
15 (each result was expressed as mean ± SD), the presence of 10 nM E2 was 
able to significantly increase the mRNA expression of progesterone receptor 
(PGR) gene compared to the blanks, which only contained 0.1% methanol 
(vehicle) in MEM supplemented with 10% charcoal-stripped FBS. PGR mRNA 
expression level with 10 nM E2 stimulation alone was considered as 100% PGR 
mRNA expression. Endoxifen was used as a positive control as it can antagonize 
the PGR mRNA expression in the presence of 10 nM E2 to 10% expression level 
compared to 10 nM E2 stimulation alone, which is consistent with the previous 
published results40. Among the 18 test compounds, norendoxifen, 
hydroxynorendoxifen, WL-V-74, WL-V-76top, WL-V-76BT1, WL-V-76BB2, WL-V-
33, WL-V-54 and WL-VI-10 were able to antagonize the PGR mRNA expression 
level to 32%, 14%, 42%, 47%, 47%, 44%, 33%, 16% and 6%, respectively. All 
the test compounds have shown statistically significant differences as compared 
to the E2 alone stimulated control. 
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Figure 15. Activity of lead norendoxifen analogues to antagonize 
progesterone receptor (PGR) mRNA expression in MCF-7 cells 
MCF-7 cells were treated with 1000 nM lead norendoxifen analogues in the 
presence of 10 nM 17β-estradiol (E2). PGR mRNA expression level with 10 nM 
E2 stimulation alone was considered as 100% PGR mRNA expression. 
Treatment with 1000 nM endoxifen was used as positive control. Data represent 
the mean ± standard deviations from 3 independent determinations. 
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5.3 Discussion 
Results summary for chapter 5 (characterization of norendoxifen 
analogues with dual aromatase inhibitory ability and estrogen receptor 
antagonistic activity): 
1) Among the 87 norendoxifen analogues, 13 compounds had both potent 
aromatase inhibitory activity and high ERs binding affinity with IC50 
(aromatase inhibition) or EC50 (binding affinity) values less than 500 nM. 
2) Among the 87 norendoxifen analogues, 14 compounds had only potent 
aromatase inhibitory activity with IC50 values less than 500 nM. 
3) Among the 87 norendoxifen analogues, 8 compounds had only high ERs 
binding affinity with EC50 values less than 500 nM. 
As we know, potent and selective AIs with limited side effects are needed 
to improve the treatment of hormone receptor-positive breast cancer in post-
menopausal women. Norendoxifen has the potential to be a therapeutically 
useful AI with fewer side effects, and in the meantime, it provides a new lead 
compound for the rational design of a series of novel compounds with dual 
aromatase inhibitory activity and ER modulatory activity. 
A series of structurally related norendoxifen analogues were tested for 
their aromatase inhibitory activity and binding affinity to ERs. Moreover, the 
antagonistic activity of norendoxifen analogues with relatively high ERs binding 
affinity was tested against estrogen-responsive genes. Among these 
norendoxifen analogues: some compounds had both potent aromatase inhibitory 
activity and high ERs binding affinity; some compounds had only potent 
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aromatase inhibitory activity; some compounds had only potent aromatase 
inhibitory activity. As shown in Figure 16 and Table 13, the structure-activity 
relationships were discussed, and this would support the development of lead 
optimization. For lead compounds with potent aromatase inhibitory activity and 
high ERs binding affinity, their chemical structures have common features: 1) -
OH group in 4’-position; 2) -OH group in 4’’-position; 3) positively charged group 
at the end of side chain at 4-position. For lead compounds with only potent 
aromatase inhibitory activity, their chemicals structures may have -NH2 group in 
4’-position, iron coordinating groups in 9-position and may not have -CH2- group 
in 4-position. Also their chemicals structures may be sensitive to the size of alkyl 
groups in 9-position and sensitive to the length of side chain at 4-position. For 
lead compounds with only high binding affinity to ERs, their chemicals structures 
may not have an -NH2 group at 4’-position or iron coordinating groups at 9-
position. 
 
 
Figure 16. Summary of structure-activity relationships 
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Table 13. Summary of structure-activity relationships 
Activity Chemical groups and their positions 
Favorable for both aromatase 
inhibitory activity and ER 
binding affinity 
-OH group at 4’-position, -OH group 
at 4’’-position, positively charged 
group at end of side chain of 4-
position 
Favorable for aromatase 
inhibitory activity only 
-NH2 group at 4’-position, iron 
coordinating groups at 9-position 
Favorable for ERs binding 
affinity only 
Insensitive to the length of side 
chain at 4-position 
 
According to our findings of the structure-activity relationships, the 
predicted chemical structure of a strong SERM/AI agent is that of 
hydroxynorendoxifen. 
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CHAPTER 6: SUMMARY AND CONCLUSIONS 
Results summary for this dissertation: 
1) Both norendoxifen and hydroxynorendoxifen are tamoxifen metabolites, 
and they are potent and relatively selective AIs with Ki values of 70 nM 
and 20 nM via a completive mechanism in vitro, respectively. 
2) Norendoxifen and hydroxynorendoxifen have high binding affinity against 
ER‐α and ER‐β, with EC50 values less than 35 nM. 
3) Norendoxifen and hydroxynorendoxifen can inhibit breast cancer cell 
proliferation with high potency, with IG50 values of 25 nM and 9 nM, 
respectively. 
4) Norendoxifen and hydroxynorendoxifen can suppress progesterone 
receptor (PGR) gene mRNA expression level by reducing 68% and 86% 
PGR mRNA expression. 
5) A series of norendoxifen analogues were developed as lead compounds 
for the development of dual AI/SERM(D) agents. 
Results from this dissertation will contribute to three aspects: 1) the 
identification of hydroxynorendoxifen as a tamoxifen metabolite illustrated a more 
comprehensive metabolism profile of tamoxifen; 2) the data suggest 
norendoxifen and hydroxynorendoxifen possess dual aromatase inhibitory and 
ER antagonistic activity; 3) a series of norendoxifen analogues were developed 
as lead compounds for the development of dual AI/SERM(D) agents. 
 
  
106 
APPENDIX (Republication permission) 
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